Your guide to peptides.

Why people are interested. 5-Amino-1MQ draws interest because blocking the enzyme NNMT might affect cell metabolism, a topic relevant to several experimental treatments.

What it’s used or studied for. Despite appearing in peptide discussions, it is a small molecule rather than a peptide. The sources included here examine cancer cells and tumor-related mechanisms.

What studies found. One laboratory study found reduced growth of cervical-cancer cells. Other research examined NNMT-related biology in bladder-cancer models. These findings do not demonstrate a benefit from taking 5-Amino-1MQ in people.

Risks and limitations. Laboratory anticancer activity cannot establish a safe cancer treatment, and it does not establish human fat-loss or anti-aging benefits. Human effectiveness and safety need direct clinical evidence.

Sources

1. Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.
2. NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer.

Why people are interested. Abaloparatide is relevant to people with osteoporosis who face an increased risk of fractures.

What it’s used or studied for. It stimulates bone formation. The European product Eladynos is authorized for postmenopausal women with osteoporosis at increased fracture risk.

What studies found. In a main study, new spinal fractures occurred in 0.5% with abaloparatide versus 4.2% with placebo after 18 months. This is a direct fracture outcome, rather than only a change in a laboratory measurement.

Risks and limitations. High calcium in the urine and dizziness are common effects; palpitations can also occur. Important restrictions apply, including some kidney problems and bone-cancer risks. These disease-specific results do not establish athletic-recovery or healthy-adult enhancement benefits.

Sources

1. EMA European public assessment report: Eladynos
2. FDA: Tymlos approval history
3. DailyMed TYMLOS (ABALOPARATIDE) INJECTION, SOLUTION [RADIUS HEALTH, INC.]

Why people are interested. Acetyl hexapeptide-8 is of interest in skincare because researchers have examined whether formulations containing it can improve the appearance of wrinkles. It has also been called acetyl hexapeptide-3.

What it’s used or studied for. The cited clinical experiment tested the ingredient in a particular hyaluronic-acid microneedle patch, rather than establishing the effectiveness of every cream containing the same peptide.

What studies found. In a randomized split-face study involving 52 Korean women, wrinkles and hydration improved across groups. The peptide-containing patch showed greater wrinkle improvement than the patch alone on some comparisons.

Risks and limitations. This was a small, formulation-specific study. It does not establish that the isolated peptide works equally well in another delivery system or that it is equivalent to an injected wrinkle treatment.

Sources

1. Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin.
2. PubChem compound 71587772: Acetyl hexapeptide-3

Why people are interested. Acetyl octapeptide-3 is of interest as an ingredient in skincare intended to improve the appearance of fine lines. The useful question is whether the finished formulation produces a noticeable benefit.

What it’s used or studied for. The cited human study evaluated a hyaluronic-acid microneedle patch containing several ingredients, including acetyl octapeptide-3, other peptides, adenosine and extracts.

What studies found. Over the study period, investigators reported improvements in measured wrinkles, hydration, skin density and thickness. These results describe the complete tested patch, not an isolated effect from acetyl octapeptide-3.

Risks and limitations. The contribution of each ingredient was not separated. A favorable result for the combined patch does not establish equivalent results from a serum, a different patch or a product delivered by injection.

Sources

1. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study.
2. PubChem compound 76283482: Acetyl octapeptide-3

Why people are interested. Acetyl tetrapeptide-5 is a cosmetic peptide whose biological activity has been investigated in skin-related laboratory experiments. Its presence on an ingredient list is a starting point for questions, not proof of a visible result.

What it’s used or studied for. The cited research evaluated individual cosmetic peptides and mixtures in human skin fibroblasts, the cells that help produce and maintain the skin’s supporting material.

What studies found. The study reported changes in laboratory measures related to oxidative stress and skin-supporting proteins. It did not measure whether people developed fewer eye bags, less swelling or fewer wrinkles.

Risks and limitations. A cell-culture result cannot establish a cosmetic benefit a person will notice. The identity records also do not establish the concentration, delivery or effectiveness of a finished product.

Sources

1. Protective and Anti-Aging Effects of 5 Cosmeceutical Peptide Mixtures on Hydrogen Peroxide-Induced Premature Senescence in Human Skin Fibroblasts.
2. PubChem compound 11620163: Acetyl tetrapeptide-5

Why people are interested. The clearest medical interest is helping people with erythropoietic protoporphyria, a rare condition in which light exposure can cause painful skin reactions. This differs from using an unverified product to obtain a tan.

What it’s used or studied for. The afamelanotide implant SCENESSE is U.S.-approved to increase pain-free light exposure in adults with a history of phototoxic reactions from that condition.

What studies found. An observational study of 115 patients reported better disease-specific quality of life during treatment. A separate randomized study tested afamelanotide alongside light therapy for vitiligo; that was a different research use.

Risks and limitations. The label warns about serious allergic reactions and increased pigmentation, including darkening of existing moles or freckles. Findings in one skin condition should not be treated as approval for another.

Sources

1. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.
2. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.
3. SCENESSE current product labeling
4. FDA: SCENESSE approval history (selected product)

Why people are interested. Albiglutide is relevant mainly when understanding the history of GLP-1 medicines for type 2 diabetes.

What it’s used or studied for. It was developed to improve blood-sugar control by mimicking a natural hormone, with a longer-lasting protein structure.

What studies found. It previously received US and EU authorization for diabetes treatment. The sources here establish its historical clinical role and later product withdrawal, rather than quantifying an individual person’s likely response.

Risks and limitations. Eperzan’s EU authorization was withdrawn for commercial reasons, and the FDA lists Tanzeum as discontinued. Historical approval does not mean it is currently available, and a commercial withdrawal does not by itself mean the medicine was ineffective.

Sources

1. EMA Eperzan withdrawal public statement
2. FDA Purple Book Tanzeum BLA 125431

Why people are interested. Amycretin, also called zenagamtide, is attracting interest as a possible future approach to weight and blood-sugar management.

What it’s used or studied for. It combines activity on GLP-1 and amylin-related pathways in one molecule. Researchers are studying whether this can build on the effects of either pathway alone.

What studies found. A phase 2 trial in people with type 2 diabetes found greater improvements in average blood sugar than placebo over 36 weeks. Separate rodent studies found weight and metabolic effects.

Risks and limitations. Animal liver and weight findings cannot be treated as established human benefits. Phase 2 success also does not settle long-term safety, broader patient outcomes or which patients would benefit most.

Sources

1. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.
2. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Why people are interested. The reason to consider angiotensin II is an emergency: dangerously low blood pressure that has not responded adequately to other hospital treatments. It is not a supplement for everyday circulation.

What it’s used or studied for. Giapreza is an EU-authorised medicine for adults with septic or other distributive shock, where blood vessels remain too relaxed to maintain adequate pressure.

What studies found. In a 344-person study, adding Giapreza helped more patients reach the blood-pressure target after three hours than adding placebo. That finding does not by itself prove longer survival.

Risks and limitations. Important risks include blood clots and temporarily excessive blood pressure. Treatment requires hospital monitoring; the evidence applies to critically ill adults.

Sources

1. Giapreza – EMA European public assessment report
2. FDA: ANGIOTENSIN ll ACETATE approval history

Why people are interested. AOD-9604 is discussed for potential fat-loss effects, but the clinical evidence deserves particular caution.

What it’s used or studied for. It is a modified growth-hormone fragment, distinct from the native hGH 176–191 sequence. FDA scientists reviewed it in connection with proposed pharmacy compounding uses.

What studies found. In the reviewed obesity evidence, FDA staff described important limitations and a lack of significant weight loss in several trial comparisons. That is a reason to question confident weight-loss promises.

Risks and limitations. The agency’s 2024 briefing and meeting discussion were scientific advisory materials, not proof of benefit or current permission to use a product. Free-base and acetate forms also require careful identification.

Sources

1. FDA Pharmacy Compounding Advisory Committee transcript, December 4 2024, Topic 2: AOD-9604-related bulk drug substances
2. FDA Briefing Document: Evaluation of AOD-9604-Related Bulk Drug Substances for the December 4, 2024 Pharmacy Compounding Advisory Committee

Why people are interested. Apraglutide is of interest to people with short bowel syndrome who need intravenous fluid or nutrition because their remaining intestine cannot absorb enough.

What it’s used or studied for. It is a long-acting GLP-2 analogue intended to improve the intestine’s ability to absorb fluid and nutrients.

What studies found. In a small randomized study of adults with short bowel syndrome-associated intestinal failure, urine output increased, supporting improved fluid absorption.

Risks and limitations. Urine output is an indirect sign of absorption, not proof that a person can stop intravenous support. The accompanying pharmacology research includes animals and does not establish clinical benefit on its own. Larger, longer studies are needed to judge durable outcomes and safety.

Sources

1. Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.
2. Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.

Why people are interested. Aviptadil attracts research interest because it may affect lung blood vessels and inflammatory responses during severe lung disease.

What it’s used or studied for. It is a synthetic version of vasoactive intestinal peptide. The included studies examine pulmonary hypertension and critical COVID-19 respiratory failure.

What studies found. A small pulmonary-hypertension study found modest, short-lived effects. An early COVID-19 trial missed its main outcome. A later US trial involving 461 treated participants was stopped for futility and found no clear improvement in its main 90-day outcome.

Risks and limitations. Encouraging secondary results do not overturn unsuccessful main outcomes. The later negative trial strengthens the need for caution; these studies do not establish a dependable treatment for severe lung disease.

Sources

1. Inhalation of vasoactive intestinal peptide in pulmonary hypertension.
2. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.
3. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial

Why people are interested. Bacitracin is relevant to readers because the same antibiotic name can appear in very different products. Its route and formulation are essential to understanding what the product is for.

What it’s used or studied for. Topical products may be labeled for first-aid infection prevention, while the former injectable product had a different medical role. A topical label is not an approval for injection.

What studies found. The primary source cited here is a regulatory safety determination, not a new effectiveness trial. FDA determined that bacitracin for injection had been withdrawn for safety or effectiveness reasons.

Risks and limitations. The injectable product raised serious kidney-toxicity and allergic-reaction concerns. That decision should not be extended to every topical or ophthalmic preparation, but it shows why the route cannot be ignored.

Sources

1. FDA: Determination That Bacitracin for Injection Was Withdrawn From Sale for Reasons of Safety or Effectiveness
2. health and .beyond Triple Antibiotic current product labeling

Why people are interested. Balixafortide has been investigated to change how cells respond to chemical signals, including in cancer treatment and stem-cell mobilisation. Interest in a mechanism is different from proof that patients benefit.

What it’s used or studied for. The phase 3 FORTRESS trial tested balixafortide with eribulin against eribulin alone in people with HER2-negative, locally recurrent or metastatic breast cancer.

What studies found. The trial was stopped early because it failed to meet its main endpoint. A separate human stem-cell study addresses another research question and cannot reverse that negative breast-cancer result.

Risks and limitations. A successful approved treatment role is not established by these sources. The failed larger trial is a central limitation, rather than a minor detail to set aside when discussing possible benefits.

Sources

1. FORTRESS balixafortide plus eribulin phase 3 study record
2. Balixafortide for stem-cell mobilisation: a dose-escalation trial in healthy volunteers

Why people are interested. Bivalirudin is considered when doctors need to limit clotting during a procedure to open narrowed heart arteries. The intended benefit is procedural protection against unwanted blood clots.

What it’s used or studied for. It blocks thrombin, a protein involved in forming clots. Its US injection label covers percutaneous coronary intervention, often called coronary angioplasty, including specified patients with heparin-related clotting complications.

What studies found. Human clinical evidence supports this defined procedural use. It does not establish a benefit from taking bivalirudin for general cardiovascular health or routine prevention outside that setting.

Risks and limitations. Bleeding is a major drawback. The balance between bleeding and clotting risk depends on the procedure, other medicines and the patient's condition.

Sources

1. Bivalirudin injection – US prescribing information
2. FDA: BIVALIRUDIN approval history

Why people are interested. BPC-157 attracts interest for injury recovery and digestive problems because animal experiments suggest effects on tissue repair. Those findings have led to questions about whether it can help people heal.

What it’s used or studied for. It is a 15-amino-acid research peptide. Human reports include knee pain and a very small intravenous safety pilot; animal and cell studies have examined stomach injury and tendon-repair processes.

What studies found. In a clinic chart review, 11 of 12 people who received BPC-157 alone reported improved knee pain. There was no comparison group or validated measurement of function. This did not demonstrate tendon repair. A separate intravenous pilot reported no short-term side effects in two adults who had previously received it.

Risks and limitations. These small, uncontrolled reports cannot establish treatment benefit or detect uncommon or long-term harms. The intravenous pilot lasted only days. A conditional draft compounding policy does not make BPC-157 an FDA-approved treatment.

BPC-157: a closer look at the human studies

Sources

1. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure.
2. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
3. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
4. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
5. FDA July 2026 PCAC scientific assessment: BPC-157-related bulk drug substances
6. HHS policy regarding 503A compounding using certain peptide bulk drug substances
7. HHS notice of availability, FR Doc 2026-22192

Why people are interested. Interest centers on low sexual desire that is distressing, rather than a general boost in sexual performance. Bremelanotide has a specific prescription-medicine role in that setting.

What it’s used or studied for. Vyleesi is approved in the United States for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder. The label excludes several other explanations for low desire.

What studies found. A small randomized crossover study reported improvements in some subjective desire and arousal measures, but not its physiological measure of vaginal blood-flow response. That experimental intranasal study differs from the approved injected product.

Risks and limitations. Nausea is common. The current label also warns about temporary blood-pressure increases and darkened patches of skin, which did not always resolve in the available follow-up.

Sources

1. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
2. Vyleesi current product labeling
3. FDA: VYLEESI (AUTOINJECTOR) approval history (selected product)

Why people are interested. Brilacidin interests researchers looking for new ways to fight difficult bacterial infections, including infections resistant to familiar antibiotics.

What it’s used or studied for. It imitates aspects of natural antimicrobial defense molecules and has been investigated for effects on bacterial membranes. It is not a conventional peptide chain.

What studies found. The sources included here show antibacterial activity in laboratory experiments and benefit in a rabbit model of a resistant bacterial eye infection. They do not establish a treatment benefit in people.

Risks and limitations. An effective laboratory concentration or an animal eye result cannot determine whether a human infection will respond. Human clinical efficacy, safety and the appropriate treatment setting need separate evidence.

Sources

1. Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16.
2. An Independent Evaluation of a Novel Peptide Mimetic, Brilacidin (PMX30063), for Ocular Anti-infective.

Why people are interested. Cagrilintide attracts interest as a possible additional way to support weight loss through the body’s fullness signals.

What it’s used or studied for. It is a long-acting version of amylin, a hormone released with food intake. Researchers study it alone and in combination with semaglutide.

What studies found. In a type 2 diabetes trial, the combination produced more weight loss than either component alone. It improved blood sugar more than cagrilintide alone, but that comparison did not show a significant advantage over semaglutide for blood sugar.

Risks and limitations. Combination benefits cannot all be attributed to cagrilintide by itself. Longer-term benefits, tolerability and the treatment setting need to be judged from the relevant clinical evidence.

Sources

1. Development of Cagrilintide, a Long-Acting Amylin Analogue.
2. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

Why people are interested. CagriSema attracts interest because combining two appetite-related medicines may improve weight and blood-sugar outcomes.

What it’s used or studied for. It combines cagrilintide and semaglutide; it is not a separate single peptide. The included phase 3 studies involve adults with type 2 diabetes.

What studies found. One trial found better average blood-sugar reduction than semaglutide alone. Another found improved blood sugar and reduced body weight when added to basal insulin, compared with placebo.

Risks and limitations. Gastrointestinal disorders were the most common unwanted effects in the active treatment groups. Findings in these diabetes populations do not automatically establish the same benefit for everyone seeking weight loss, and the combination must be considered alongside existing medicines.

Sources

1. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
2. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

Why people are interested. Salmon calcitonin is relevant to bone health because it slows the activity of cells that break down bone.

What it’s used or studied for. Specific nasal and injectable medicines have been used for particular bone and calcium disorders. Their indications differ by formulation and country.

What studies found. A small randomized study in fifty older women after a hip fracture found differences in bone-turnover measurements and bone density. That study alone cannot establish broad prevention of future fractures.

Risks and limitations. Nasal and injectable findings are not interchangeable. The injection label includes serious allergic reactions, and safety information differs between formulations. This is a disease-specific medicine rather than a general bone-strengthening or exercise-recovery treatment.

Sources

1. The effects of calcitonin on acute bone loss after pertrochanteric fractures. A prospective, randomised trial.
2. FDA: CALCITONIN-SALMON approval history
3. MIACALCIN (CALCITONIN SALMON) INJECTION, SOLUTION [MYLAN INSTITUTIONAL LLC]

Why people are interested. Carnosine interests researchers because it can take part in chemical processes involving oxidation. That has motivated questions about aging and tissue protection, but a chemical effect is not the same as a proven health benefit.

What it’s used or studied for. It is a dipeptide made from beta-alanine and histidine. The cited research examined antioxidant activity of carnosine and related molecules in laboratory assays.

What studies found. The experiment found antioxidant activity under the tested conditions. It did not show that people who use a carnosine supplement or skincare product live longer, avoid disease or develop fewer wrinkles.

Risks and limitations. These sources do not establish a useful dose, long-term benefit or the safety of every formulation. Claims about a particular supplement or cosmetic require human evidence for that actual use.

Sources

1. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain.
2. PubChem compound 439224: Carnosine

Why people are interested. Cerebrolysin is discussed in neurological rehabilitation because researchers have asked whether it can improve recovery after injuries such as stroke. It is a mixture of peptides, not one precisely defined peptide.

What it’s used or studied for. The cited human studies tested it in acute ischemic stroke, including a study combined with alteplase. That evidence cannot automatically be extended to other brain conditions or healthy people.

What studies found. A trial involving 1,070 patients found no significant difference on its main combined outcome. Another study stopped after an interim analysis did not show the expected benefit on its main day-90 disability measure.

Risks and limitations. Some secondary outcomes or subgroups appeared more favorable, but they do not erase the neutral main results. Product status varies by country and cannot be inferred from these trials alone.

Sources

1. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.
2. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.

Why people are interested. Cetrorelix is considered during fertility treatment to prevent eggs being released before they can be collected. Timing matters because eggs released too early may be unsuitable for planned treatment.

What it’s used or studied for. Cetrotide blocks the hormonal signal that triggers ovulation. EMA authorises it for women receiving ovarian stimulation, where medicines encourage several eggs to develop.

What studies found. Human fertility studies supported its ability to prevent premature ovulation, and EMA judged it an effective alternative to existing treatments. Preventing early egg release does not guarantee pregnancy or a live birth.

Risks and limitations. Injection-site reactions can occur, and severe allergic reactions are an important concern. Ovarian overstimulation can also occur within the wider fertility-treatment process.

Sources

1. Cetrotide – EMA public assessment report
2. FDA: CETRORELIX ACETATE approval history

Why people are interested. CJC-1295 attracts attention because it can stimulate release of growth hormone, a hormone involved in growth and metabolism.

What it’s used or studied for. Human studies have investigated long-acting forms linked to an albumin-binding modification called DAC. Products described as being without DAC are chemically different.

What studies found. Small studies in healthy adults found hormone changes. Another publication examined changes in blood proteins in eleven men. These measurements did not establish treatment benefits for growth hormone deficiency, muscle recovery or aging.

Risks and limitations. Reported effects in small healthy-adult studies included injection-site reactions, headache, flushing and temporary low blood pressure. The exact chemical forms were not always clear. Long-term safety remains uncertain, and hormone changes do not prove improved strength, function or recovery.

Sources

1. FDA December 2024 PCAC scientific assessment: CJC-1295-related substances
2. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Why people are interested. GHK-Cu is a copper-linked peptide of interest for skin appearance and wound repair. It is also called copper tripeptide-1. Its effects depend on the formulation and how it reaches the skin.

What it’s used or studied for. Human research has tested topical products after laser skin resurfacing and a particular gel added to standard care for diabetic foot ulcers. These are different settings from everyday anti-aging skin care.

What studies found. In an older ulcer trial, the gel improved wound-area closure compared with its base gel alongside standard wound care. In a randomized post-laser study completed by 13 people, GHK-Cu did not show a significant objective improvement in redness, wrinkles or skin quality compared with the control regimen, although satisfaction was higher.

Risks and limitations. These results concern particular topical products and patient groups. They do not show that every copper-peptide cream works, that GHK-Cu reverses aging, or that injecting it is safe or effective.

Sources

1. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures.
2. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways.
3. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.
4. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.

Why people are interested. Corticotropin is relevant in specialized treatment, including infantile spasms, a serious seizure disorder in very young children.

What it’s used or studied for. Repository corticotropin is a complex hormone-related preparation that stimulates adrenal activity; it is not a single synthetic wellness peptide.

What studies found. FDA records document approval for the specific infantile-spasm indication. That establishes a defined clinical use, not evidence that it broadly improves immunity, energy or healthy aging.

Risks and limitations. The prescribing information describes substantial steroid-related effects and important restrictions, including some infections and uncontrolled high blood pressure. Treatment requires specialist supervision, and the exact product and disease matter when interpreting any benefit claim.

Sources

1. FDA orphan designation and approval record: repository corticotropin
2. FDA: H.P. ACTHAR GEL approval history
3. DailyMed ACTHAR (REPOSITORY CORTICOTROPIN) INJECTION ACTHAR (REPOSITORY CORTICOTROPIN) INJECTION [KEENOVA ARD LLC]

Why people are interested. Cosyntropin is useful when clinicians need to find out whether the adrenal glands can make enough cortisol.

What it’s used or studied for. It is a synthetic fragment of ACTH used to stimulate cortisol release during a diagnostic test. It is not a treatment for ordinary tiredness.

What studies found. Human diagnostic studies show that the laboratory method used to measure cortisol changes how the test should be interpreted. A result judged using the wrong reference range can be misleading.

Risks and limitations. A stimulation test helps answer a diagnostic question; it does not itself correct an adrenal disorder. Symptoms, other medicines and assay-specific interpretation need to be assessed together by a clinician.

Sources

1. New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays.
2. The Short Cosyntropin Test Revisited: New Normal Reference Range Using LC-MS/MS.
3. FDA: CORTROSYN approval history
4. CORTROSYN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [HENRY SCHEIN, INC.]

Why people are interested. Cyclosporine is relevant to people who need suppression of immune activity, especially in transplant care where rejection can threaten a donated organ.

What it’s used or studied for. It reduces certain immune-cell signals. The included studies examine kidney-transplant treatment regimens and changes in graft survival over time.

What studies found. A large randomized comparison found that a tacrolimus-based regimen had advantages over the cyclosporine-based regimens tested for several transplant outcomes. This helps place cyclosporine among treatment options rather than showing it is always best.

Risks and limitations. These are complex combinations of medicines, so an outcome cannot be attributed to one drug alone. Suppressing immunity requires specialist monitoring and a careful balance between treatment benefit and unwanted effects.

Sources

1. Reduced exposure to calcineurin inhibitors in renal transplantation.
2. Improved graft survival after renal transplantation in the United States, 1988 to 1996.
3. FDA: CYCLOSPORINE approval history (selected product)

Why people are interested. These antibiotics interest clinicians treating certain bacterial infections, particularly when the bacteria and clinical situation fit the medicine. They are three separate drugs, not one interchangeable peptide.

What it’s used or studied for. Dalbavancin, oritavancin and telavancin have product-specific approvals for defined infections. The cited randomized studies examined bacterial skin and skin-structure infections in selected patient groups.

What studies found. Each additional trial compared one of the drugs with an established antibiotic and reported comparable clinical results within the study design. A favorable comparison does not establish superiority or usefulness for every infection.

Risks and limitations. Safety and practical considerations differ. Telavancin carries major kidney-related and pregnancy-related warnings. The exact product, infection, organism and patient circumstances matter more than membership in the same antibiotic group.

Sources

1. Single-dose oritavancin in the treatment of acute bacterial skin infections.
2. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
3. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
4. Dalbavancin current product labeling
5. Kimyrsa current product labeling
6. VIBATIV current product labeling
7. FDA: DALVANCE approval history (selected product)
8. FDA: KIMYRSA approval history (selected product)
9. FDA: VIBATIV approval history (selected product)

Why people are interested. Daptomycin is considered in care for certain serious bacterial infections, including selected skin infections and bloodstream infections. It is an antibiotic medicine, not an anti-aging or general health peptide.

What it’s used or studied for. Its U.S. product labeling covers specified complicated skin infections and Staphylococcus aureus bloodstream infections in defined adult and pediatric populations.

What studies found. Two randomized trials involving 1,092 patients with complicated skin infections reported clinical success comparable with conventional antibiotics in the evaluated population. This does not answer every bloodstream-infection question.

Risks and limitations. The product label warns about muscle injury, including severe muscle breakdown, and a serious inflammatory lung reaction called eosinophilic pneumonia. These risks are separate from whether the antibiotic is likely to work for the infection.

Sources

1. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
2. Daptomycin current product labeling
3. FDA: DAPTOMYCIN approval history (selected product)

Why people are interested. Dasiglucagon was developed to make treatment of dangerously low blood sugar easier, using a liquid formulation ready for emergency use.

What it’s used or studied for. It is a modified version of glucagon, the hormone that raises blood sugar, studied in adults and children with type 1 diabetes.

What studies found. In a pediatric trial, median blood-sugar recovery took 10 minutes with dasiglucagon versus 30 minutes with placebo. Adult research also found a rapid response comparable to standard glucagon.

Risks and limitations. Nausea was common in the adult study. Controlled low-blood-sugar experiments cannot capture every emergency situation. The checked US FDA product entries list Zegalogue as discontinued, so availability needs separate confirmation.

Sources

1. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
2. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.
3. FDA: ZEGALOGUE approval history (selected product)

Why people are interested. Davunetide attracted research interest because protecting nerve-cell function might help problems with thinking or everyday functioning in neurological and psychiatric conditions. That remains a research question.

What it’s used or studied for. Also called NAP or AL-108, it has been tested in people with schizophrenia and studied in animal models of neurodegeneration. These are distinct settings, not one proven use.

What studies found. In a 63-person schizophrenia trial, the main thinking-skills test did not improve significantly compared with placebo. One measure of practical functional ability favored treatment.

Risks and limitations. The mixed results do not establish a cognitive enhancer or an approved treatment. Findings from mice cannot fill the gaps in human effectiveness or long-term safety.

Sources

1. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
2. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.

Why people are interested. Degarelix is considered when prostate cancer depends on testosterone to grow. Its purpose is to reduce that hormonal support, rather than raise testosterone or improve general vitality.

What it’s used or studied for. Firmagon blocks the hormone-signalling pathway that drives testosterone production. EMA describes its use in specified hormone-dependent prostate-cancer settings, including treatment around radiotherapy.

What studies found. Human studies found it effective at lowering testosterone. In a separate 244-person study, prostate shrinkage before radiotherapy was similar to that with goserelin plus bicalutamide.

Risks and limitations. Hot flushes and injection-site pain or redness are common. Benefits and burdens belong in the context of cancer care; testosterone reduction is not a general health benefit for otherwise healthy people.

Sources

1. Firmagon – EMA public assessment report
2. FDA: FIRMAGON approval history

Why people are interested. Desirudin was developed to prevent dangerous leg-vein clots after planned hip replacement. Such clots can travel to the lungs, so prevention is a specific surgical need.

What it’s used or studied for. The historical US Iprivask label describes this clot-prevention use. Desirudin blocks thrombin, part of the body's clot-forming system.

What studies found. Human studies supported its historical approval for hip-replacement patients. That does not establish a role in general circulation, wellness or every type of surgery.

Risks and limitations. Bleeding is an important risk, including potentially disabling bleeding around the spine with spinal or epidural procedures. Iprivask is listed as discontinued, so historical approval should not be confused with a currently marketed treatment.

Sources

1. Iprivask (desirudin): historical FDA prescribing information, 2014
2. FDA: IPRIVASK approval history

Why people are interested. Desmopressin can be useful when the body needs help retaining water or, in selected bleeding disorders, temporarily improving clotting. These are distinct medical reasons for interest.

What it’s used or studied for. The injection label covers central diabetes insipidus, a condition causing excessive urine production because a water-regulating hormone is lacking, and defined patients with haemophilia A or type I von Willebrand disease.

What studies found. Human evidence supports those specific uses. It does not support treating every cause of thirst, frequent urination or bleeding, and findings for an injection cannot automatically be applied to other formulations.

Risks and limitations. A major danger is dangerously low blood sodium, which can cause severe illness. Fluid balance and sodium require clinical oversight.

Sources

1. Desmopressin acetate injection – US prescribing information
2. FDA: DESMOPRESSIN ACETATE approval history

Why people are interested. Difelikefalin is relevant to people whose kidney-disease-related itching is severe enough to affect comfort, sleep or quality of life while receiving hemodialysis.

What it’s used or studied for. KORSUVA is U.S.-approved for moderate-to-severe itching associated with chronic kidney disease in adults undergoing hemodialysis. That is a narrower situation than itching in general.

What studies found. Randomized phase 2 studies reported reduced itch severity compared with placebo, with some improvements in itch-related quality of life and sleep measurements. The results apply to the dialysis populations studied.

Risks and limitations. Treatment groups also experienced adverse effects. The studies reported problems including diarrhea, dizziness, nausea, sleepiness and falls. The benefit cannot be assumed for other causes of itching or other dialysis settings.

Sources

1. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients.
2. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
3. Korsuva current product labeling
4. FDA: KORSUVA approval history (selected product)

Why people are interested. Dihexa has attracted interest around memory and nerve repair because it acts on pathways involved in cell growth and signaling. The available results need to be distinguished from claims of human cognitive enhancement.

What it’s used or studied for. Also described as PNB-0408, it is an angiotensin-IV-related compound. The additional cited experiments tested combinations in nerve-injured rats and a toxin-induced model of Huntington-like symptoms.

What studies found. These papers were not human trials. A nerve-repair experiment reported improved motor outcomes with a combination involving stem cells, while the Huntington-like rat study found no protection against the induced deficits.

Risks and limitations. The findings are mixed and condition-specific. They do not show that people will remember better or recover from neurological disease, and they do not establish clinical safety.

Sources

1. Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies.
2. Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats.

Why people are interested. This long ingredient name is associated with the cosmetic peptide mimic Syn-Ake. Interest centers on whether it might improve skin appearance, but the mechanism proposed in a laboratory does not establish that benefit.

What it’s used or studied for. The cited study used computer modeling, antioxidant testing and laboratory safety assays to investigate interactions with proteins discussed in skin-aging research.

What studies found. That work did not test wrinkle improvement in people. Its reported protein-binding predictions and antioxidant activity are early research findings, not measured cosmetic results in a clinical trial.

Risks and limitations. Computer models and laboratory tests cannot establish equivalence to botulinum toxin, long-term safety or the performance of a finished cream. Those questions need direct evidence in the relevant people and formulation.

Sources

1. Anti-aging activity of Syn-Ake peptide by <i>in silico</i> approaches and <i>in vitro</i> tests.
2. PubChem compound 71465152: Dipeptide diaminobutyroyl benzylamide diacetate

Why people are interested. DSIP, short for delta sleep-inducing peptide, attracts interest because of its name and early research on sleep. Whether it provides meaningful relief for present-day sleep problems is a separate question.

What it’s used or studied for. It was investigated in small experiments measuring sleep and other physiological responses. The cited human work dates to the early 1980s.

What studies found. One double-blind crossover study involved six healthy volunteers and reported changes in sleep timing and sleep measurements. Another publication described several early human experiments, rather than a large modern insomnia trial.

Risks and limitations. Small, old studies cannot establish reliable benefit for a broad population or long-term safety. Their reported tolerability does not mean a currently marketed research product is safe or effective.

Sources

1. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.
2. Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep.

Why people are interested. Dulaglutide interests people with type 2 diabetes who need better blood-sugar control and, in some cases, lower cardiovascular risk.

What it’s used or studied for. Trulicity mimics GLP-1 and has specific diabetes and cardiovascular indications in its US prescribing information.

What studies found. Regulator-reviewed trials found improved blood-sugar control. In a large cardiovascular study, major events occurred in 12.0% with dulaglutide versus 13.4% with placebo over about five years.

Risks and limitations. Nausea, vomiting and diarrhea are common. The US label also carries a thyroid-tumor warning based on animal findings, with specific restrictions for certain thyroid-cancer histories; the human risk is uncertain. Benefits in diabetes do not establish healthy-person enhancement.

Sources

1. EMA European public assessment report: Trulicity
2. FDA: Trulicity approval history
3. DailyMed TRULICITY (DULAGLUTIDE) INJECTION, SOLUTION [ELI LILLY AND COMPANY]

Why people are interested. Ecallantide is of interest to people managing hereditary angioedema because an acute attack can cause significant swelling and distress. Its role is specific to that condition.

What it’s used or studied for. The U.S.-approved product KALBITOR treats acute hereditary-angioedema attacks in patients age 12 and older. It inhibits kallikrein, part of the pathway involved in these attacks.

What studies found. Placebo-controlled studies reported greater improvement in attack-symptom measures with ecallantide in the studied populations. These findings concern acute attacks, not general swelling or routine prevention.

Risks and limitations. The product carries a boxed warning for anaphylaxis, a potentially severe allergic reaction that can resemble the illness being treated. It requires administration by a healthcare professional with appropriate medical support.

Sources

1. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
2. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
3. Kalbitor current product labeling
4. FDA: KALBITOR approval history (selected product)

Why people are interested. People may encounter echinocandins when a fungal infection needs prescription treatment. The potential benefit is killing susceptible fungi by disrupting the protective wall around their cells.

What it’s used or studied for. Echinocandins are a medicine class, including caspofungin, micafungin, anidulafungin and rezafungin. They are not one compound with a single shared set of uses.

What studies found. These medicines have established clinical roles, but the right choice depends on the fungus and infection site. The cited CDC overview explains their action; it does not provide one success rate that applies to every member or infection.

Risks and limitations. Antifungal treatment can cause side effects and requires careful selection. Class membership does not make different products interchangeable or establish a benefit for routine wellness.

Sources

1. Clinical Treatment of Fungal Diseases: Antifungals
2. FDA: CASPOFUNGIN ACETATE approval history

Why people are interested. Efpeglenatide attracts interest as a long-acting approach to improving blood sugar and body weight.

What it’s used or studied for. It activates the GLP-1 pathway and has been studied in type 2 diabetes and in adults with overweight or obesity.

What studies found. A phase 2 placebo-controlled diabetes trial found improvements in average blood sugar and weight. A separate weight-management trial studied adults without diabetes alongside a reduced-calorie diet.

Risks and limitations. Short trials cannot establish long-term safety, durable weight loss or the best treatment for an individual. Publication of promising results does not itself establish current marketing authorization. The outcomes also need to be interpreted in the context of the study population and accompanying lifestyle intervention.

Sources

1. Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.
2. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study

Why people are interested. Elamipretide interests researchers studying mitochondria, the energy-producing structures inside cells, but its approved use is narrowly defined.

What it’s used or studied for. In the US, Forzinity received accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.

What studies found. The small randomized study did not beat placebo on its main walking-distance and fatigue outcomes. Approval relied on a muscle-strength measure, with longer open-label observations informing the assessment.

Risks and limitations. Confirmatory clinical benefit still needs verification. This rare-disease approval does not establish an anti-aging, general energy or athletic-performance treatment. A small uncontrolled extension cannot provide the same certainty as a successful randomized trial.

Sources

1. FDA Drug Trials Snapshot: Forzinity
2. FDA Forzinity accelerated approval letter NDA 215244
3. DailyMed FORZINITY (ELAMIPRETIDE HYDROCHLORIDE) INJECTION [STEALTH BIOTHERAPEUTICS INC.]

Why people are interested. Enfuvirtide is relevant to HIV treatment when previous antiretroviral medicines have stopped working adequately.

What it’s used or studied for. It blocks an early step in HIV entering cells and was studied as an addition to an individually optimized background regimen.

What studies found. In treatment-experienced people with HIV-1, adding enfuvirtide improved viral suppression and immune-system measures over 24 weeks compared with the background regimen alone.

Risks and limitations. Early research also documented rapid emergence of resistance, highlighting the importance of an effective combination regimen. It is not a stand-alone cure or a general immune booster. The checked US FDA Fuzeon product entry is listed as discontinued, so present availability requires separate confirmation.

Sources

1. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
2. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
3. FDA: FUZEON approval history (selected product)

Why people are interested. Enlicitide interests people who need additional lowering of LDL cholesterol, often called bad cholesterol, and would prefer an oral option.

What it’s used or studied for. It blocks PCSK9, a protein involved in how the body clears LDL cholesterol. The included trial studied adults with inherited high cholesterol despite existing treatment.

What studies found. At 24 weeks, LDL cholesterol fell by about 58% with enlicitide while rising slightly with placebo. Participants were already taking statins, and many also took another cholesterol medicine.

Risks and limitations. Lower cholesterol is not the same outcome as directly showing fewer heart attacks. These results apply to the trial population, and medicine selection still depends on overall cardiovascular risk and existing treatment.

Sources

1. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
2. Total Synthesis of Enlicitide Decanoate.
3. FDA: LIPFENDRA approval history (selected product)

Why people are interested. Epitalon, also spelled epithalon, attracts interest around aging and sleep because researchers have studied cell activity and melatonin, a hormone involved in the sleep-wake cycle.

What it’s used or studied for. It is a short peptide also called AEDG. Research includes lifespan experiments in fruit flies, laboratory cell studies and a small human study involving mostly night-shift workers.

What studies found. In a study involving 75 middle-aged women, a 40-person subgroup with low melatonin production received AEDG or placebo. AEDG increased a urine marker of melatonin production. The study did not measure how well or how long participants slept.

Risks and limitations. A hormone-marker change does not prove better sleep or a longer life. The study was short, blinding was not specified, and it used an under-the-tongue preparation rather than injections. Long-term benefit and safety remain uncertain.

Sources

1. Effect of epitalon on the lifespan increase in Drosophila melanogaster.
2. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism.
3. FDA July 2026 PCAC scientific assessment: epitalon-related bulk drug substances
4. AEDG Peptide Regulation of the Expression of Human Circadian Rhythm Genes upon Accelerated Aging of the Pineal Gland.

Why people are interested. Eptifibatide is considered in hospital heart care when preventing an additional blood clot may reduce the risk of a heart attack. It works on platelets, the blood cells that stick together to form clots.

What it’s used or studied for. EMA describes Eptifibatide Accord for defined adults with unstable angina or a particular type of recent heart attack, alongside other antithrombotic treatment.

What studies found. Its clinical rationale and authorisation concern these acute, higher-risk patients. The generic product relies on the established evidence for its reference medicine; this is not evidence of benefit for every person with heart disease.

Risks and limitations. Bleeding risk and kidney function affect suitability. It belongs in monitored specialist treatment, rather than general heart-health self-care.

Sources

1. Eptifibatide Accord – EMA public assessment report
2. FDA: EPTIFIBATIDE approval history

Why people are interested. Etelcalcetide addresses a complication of advanced kidney disease: excessive parathyroid hormone, which disrupts the body’s calcium and phosphate balance.

What it’s used or studied for. The approved medicine Parsabiv is used for secondary hyperparathyroidism in adults receiving hemodialysis, a treatment that filters the blood when kidneys cannot do so adequately.

What studies found. The EMA describes controlled studies in dialysis patients showing greater reductions in parathyroid hormone than placebo. These are findings in a specific kidney-disease population.

Risks and limitations. Lowering a hormone measurement does not itself prove fewer fractures or better survival. Low blood calcium, muscle spasms, nausea and vomiting are recognized risks. These results do not establish a benefit for healthy adults.

Sources

1. FDA: Parsabiv approval history
2. EMA Parsabiv European public assessment overview
3. PARSABIV (ETELCALCETIDE) INJECTION, SOLUTION [AMGEN, INC]

Why people are interested. Exenatide is relevant to blood-sugar treatment in type 2 diabetes and to understanding earlier GLP-1 medicines.

What it’s used or studied for. It mimics a hormone involved in glucose control. Different formulations and combination products are separate medicines and should not be treated as one interchangeable product.

What studies found. Its past authorization reflects a defined diabetes use. The regulator sources included here focus on that clinical role and product status rather than supplying a new head-to-head benefit estimate.

Risks and limitations. The EU authorization for Byetta was withdrawn in January 2026 for commercial reasons. That does not determine the availability or status of every exenatide product worldwide, and it is not evidence for general weight-loss or wellness use.

Sources

1. EMA European public assessment report: Byetta
2. FDA: BYETTA approval history

Why people are interested. Follistatin attracts research interest because it can block signals that limit muscle growth, making it relevant to investigations of muscle disease.

What it’s used or studied for. Follistatin-344 describes a protein precursor. Some clinical research has instead delivered a gene so cells produce follistatin; that is a different intervention from administering a protein.

What studies found. The additional sources reviewed explain the human gene and its different protein forms. They do not establish muscle-growth benefits from injecting a commercially offered follistatin-344 product.

Risks and limitations. The precursor is processed into a shorter protein, so names can obscure important differences. Findings from gene delivery cannot establish the same effects, safety or duration for a protein preparation. An approved enhancement use is not established.

Sources

1. Primary structure of the human follistatin precursor and its genomic organization.
2. UniProtKB P19883: Follistatin

Why people are interested. Fragment 176–191 is discussed for possible metabolic or fat-loss effects, but the exact molecule and the outcome measured are important.

What it’s used or studied for. It is a native end fragment of human growth hormone. It should not be assumed to be identical to the modified peptide AOD-9604.

What studies found. The included research examines rat glucose and insulin responses and a breast-cancer cell experiment involving nanoparticles. Neither study demonstrates clinical weight loss in people.

Risks and limitations. The rat study actually found short-lived blood-sugar increases and changes in insulin response, rather than establishing a desirable fat-loss treatment. Cell and animal findings cannot establish human benefit, long-term safety or an appropriate treatment regimen.

Sources

1. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.
2. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone.

Why people are interested. Gallium-68 dotatate can help doctors locate certain neuroendocrine tumors and understand how far they have spread.

What it’s used or studied for. It is a radioactive imaging tracer used with PET/CT scans, rather than a supplement or a medicine intended to shrink tumors.

What studies found. In a prospective study of 131 patients, it detected more tumor lesions than the comparison imaging methods. Another small study found that its usefulness varied with tumor type and grade.

Risks and limitations. A scan result does not itself treat cancer. Different tumors take up different tracers, and the strongest imaging approach can depend on tumor biology. Specialist interpretation and the wider diagnostic picture remain essential.

Sources

1. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
2. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
3. FDA: NETSPOT approval history (selected product)

Why people are interested. Ganirelix helps fertility teams control when ovulation happens. Its role is to stop eggs being released prematurely while the ovaries are being stimulated to develop eggs for assisted reproduction.

What it’s used or studied for. EMA describes Orgalutran for women undergoing controlled ovarian stimulation. It blocks a hormonal signal that would otherwise trigger early egg release.

What studies found. Human studies supported its ability to prevent premature ovulation, leading to EU authorisation. This is a treatment-process benefit; it should not be interpreted as a promise that an individual will become pregnant.

Risks and limitations. Redness and swelling at the injection site are common. It forms part of a monitored fertility-treatment programme, and its benefits cannot be transferred to unrelated hormone or wellness goals.

Sources

1. Orgalutran – EMA public assessment report
2. FDA: FYREMADEL approval history

Why people are interested. GHK-Cu is a copper-linked peptide of interest for skin appearance and wound repair. It is also called copper tripeptide-1. Its effects depend on the formulation and how it reaches the skin.

What it’s used or studied for. Human research has tested topical products after laser skin resurfacing and a particular gel added to standard care for diabetic foot ulcers. These are different settings from everyday anti-aging skin care.

What studies found. In an older ulcer trial, the gel improved wound-area closure compared with its base gel alongside standard wound care. In a randomized post-laser study completed by 13 people, GHK-Cu did not show a significant objective improvement in redness, wrinkles or skin quality compared with the control regimen, although satisfaction was higher.

Risks and limitations. These results concern particular topical products and patient groups. They do not show that every copper-peptide cream works, that GHK-Cu reverses aging, or that injecting it is safe or effective.

Sources

1. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures.
2. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways.
3. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.
4. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.

Why people are interested. GHRP-2, also called pralmorelin, stimulates growth hormone release. That makes it useful for studying how the hormone system responds to a challenge.

What it’s used or studied for. Japan has a prescription pralmorelin-hydrochloride product used to diagnose growth hormone deficiency. This diagnostic use is different from long-term hormone treatment.

What studies found. A separate small human physiology study measured appetite, food intake and hormone responses during short experimental infusions. It did not establish lasting improvements in muscle, recovery or aging.

Risks and limitations. An acute hormone response is not proof of clinical benefit from repeated use. Japan’s diagnostic authorization does not establish approval for other purposes or in other countries; the exact product and intended use matter.

Sources

1. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake.
2. PMDA: GHRP KAKEN100 Injection (pralmorelin hydrochloride) prescribing information

Why people are interested. GHRP-6 stimulates growth hormone release and has helped researchers explore how that hormone responds to age, exercise and other signals.

What it’s used or studied for. It is a synthetic six-amino-acid peptide, distinct from GHRP-2 and hexarelin. The additional studies reviewed involved short experiments in small groups of people.

What studies found. One study compared younger and older adults; another examined hormone responses around exercise in healthy men. They measured acute endocrine responses, rather than improvements in strength, injury recovery or daily function.

Risks and limitations. These experiments do not establish a useful long-term treatment or enhancement benefit. Short observation periods and small samples cannot settle chronic safety, and changing a hormone level does not establish a better health outcome.

Sources

1. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood.
2. Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release.

Why people are interested. Glepaglutide is of interest to people with short bowel syndrome who struggle to absorb enough fluid and nutrients.

What it’s used or studied for. It is a long-acting version of the intestinal-support hormone GLP-2. Researchers are studying whether it can improve absorption and reduce intestinal fluid losses.

What studies found. An early randomized study found improved intestinal absorption at some of the tested treatment levels. Related research suggested slower movement through the gut, which may help explain improved absorption.

Risks and limitations. Early improvements in absorption do not guarantee lasting independence from intravenous support. The studies were limited in size and duration, so longer trials are needed to clarify the overall balance of benefit and unwanted effects.

Sources

1. Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.
2. Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial.

Why people are interested. Glucagon matters because severe low blood sugar can become an emergency when a person cannot safely eat or drink.

What it’s used or studied for. It is a natural hormone used in rescue medicines to raise blood sugar. Researchers also study it alongside insulin in automated diabetes systems.

What studies found. Two trials found a ready-to-use glucagon autoinjector restored blood sugar within 30 minutes at a rate comparable to a traditional emergency kit. A small automated-system study reduced low blood sugar around exercise.

Risks and limitations. The automated system also increased time with high blood sugar in some comparisons, and nausea led some participants to withdraw. Results for one formulation or device do not automatically apply to another.

Sources

1. Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies.
2. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.
3. FDA: BAQSIMI approval history (selected product)

Why people are interested. Interest in glutathione often centers on antioxidant biology or cosmetic skin lightening. Those are different questions, and results from one preparation should not be treated as evidence for another.

What it’s used or studied for. Glutathione is a naturally occurring three-amino-acid molecule involved in cellular redox processes. The additional human study cited here investigated a specific preparation used by 30 Filipino women.

What studies found. The study reported a reduction in measured skin-pigment indices during eight weeks. It was open-label and had no comparison group, so it cannot show how much change was caused by glutathione itself.

Risks and limitations. The study was small and short. It does not establish lasting cosmetic benefit, long-term safety, or the benefit or safety of intravenous products marketed for skin lightening.

Sources

1. An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women.
2. PubChem compound 124886: Glutathione

Why people are interested. Gonadorelin interests researchers because it can replace a missing reproductive-hormone signal in particular disorders. The important question is whether that benefit applies to a proposed preparation and patient group.

What it’s used or studied for. A study examined pulsatile GnRH treatment in 28 men born with deficient hormone signalling, a condition called congenital hypogonadotropic hypogonadism. Pulsatile means delivery in timed bursts.

What studies found. Over seven days, reproductive-hormone levels increased. The small study had no separate control group and did not establish long-term fertility outcomes or benefit as an add-on to testosterone replacement.

Risks and limitations. Historical Factrel products are discontinued. These findings do not establish that a compounded preparation is approved, reliably sterile or effective for a different use.

Sources

1. Pulsatile GnRH therapy in congenital hypogonadotropic hypogonadism: a multicentre clinical study
2. FDA: FACTREL approval history

Why people are interested. Goserelin is considered when lowering sex hormones can help control a hormone-sensitive cancer. The aim is to slow cancer growth or relieve its effects, rather than improve hormone levels in a healthy person.

What it’s used or studied for. NCI describes approved uses in prostate cancer and advanced breast cancer in specified women before or around menopause. Some prostate-cancer uses involve other treatments as well.

What studies found. With continued treatment, goserelin lowers testosterone or oestrogen, reducing signals that some cancer cells need to grow. Approved uses are specific to the cancer and treatment setting.

Risks and limitations. Hormone levels initially rise before falling. The intended hormone suppression is itself a major treatment change, and the brief NCI overview is not a complete account of side effects.

Sources

1. Goserelin acetate: NCI cancer-drug information
2. FDA: ZOLADEX approval history

Why people are interested. For someone comparing peptide skincare, the exact ingredient name matters. Regular hexapeptide-9 and a modified, cyclized version are different materials, so evidence about one should not automatically be assigned to the other.

What it’s used or studied for. Hexapeptide-9 is a defined peptide also associated with the name Collaxyl. The cited authoritative records establish its identity and naming.

What studies found. These identity records do not report cosmetic treatment results in people. They do not answer whether an ordinary hexapeptide-9 formulation reduces wrinkles, improves firmness or changes skin hydration.

Risks and limitations. An ingredient name alone does not describe a finished product’s concentration, delivery or performance. A separate study is needed to establish a clinical benefit, and identity registration is not approval as a medicine.

Sources

1. PubChem compound 16129319: Hexapeptide-9
2. FDA GSRS substance identity: Hexapeptide-9

Why people are interested. Hexarelin, also called examorelin, interests researchers because it can trigger release of growth hormone and illuminate the signaling behind that response.

What it’s used or studied for. It is a synthetic six-amino-acid research peptide. Early human experiments examined the magnitude of the hormone response and differences between administration routes.

What studies found. Two small studies in healthy volunteers measured acute growth hormone release. These are observations in people, but they did not establish better muscle function, recovery, heart health or aging outcomes.

Risks and limitations. A short-term hormone response cannot show the benefits or risks of repeated use. Different routes may produce different effects. The reviewed sources do not establish an approved treatment or justify performance-enhancement claims.

Sources

1. Growth hormone-releasing activity of hexarelin in humans. A dose-response study.
2. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.

Why people are interested. Histrelin may be considered for children whose puberty starts abnormally early because the normal puberty-signalling system switches on too soon. The goal is to slow that premature progression.

What it’s used or studied for. The cited patient guide describes a histrelin implant for central precocious puberty, which can cause early sexual development and faster-than-normal bone growth.

What studies found. The medicine reduces the hormones driving puberty. Its established clinical role concerns children with this diagnosed condition, rather than a general benefit from suppressing hormones or delaying normal development.

Risks and limitations. The implant requires insertion and removal procedures. Pain, swelling or scarring can occur, and puberty signs can temporarily worsen at the start. Serious reactions, including seizures, are also described.

Sources

1. Histrelin Implant – MedlinePlus Drug Information
2. FDA: SUPPRELIN LA approval history

Why people are interested. Human chorionic gonadotropin, or hCG, is of interest in fertility treatment because it can trigger the final steps leading to egg release. It is a hormone used in different preparations, not one interchangeable product.

What it’s used or studied for. EMA describes Ovitrelle, a manufactured version called choriogonadotropin alfa, for specified women receiving fertility treatment or needing help to ovulate.

What studies found. Studies in fertility patients found Ovitrelle similarly effective to urinary-derived hCG at triggering ovulation. Egg release is an intermediate result, not a guarantee of pregnancy or live birth.

Risks and limitations. Ovarian hyperstimulation can cause illness when the ovaries overrespond. Abdominal symptoms and injection-site reactions also occur. These findings do not establish weight-loss or general wellness benefits.

Sources

1. Ovitrelle – EMA public assessment report
2. FDA: PREGNYL approval history

Why people are interested. Humanin interests researchers investigating why some nerve cells resist damage associated with Alzheimer-related biology.

What it’s used or studied for. It is a small mitochondrial-associated peptide studied in cell-protection experiments. Natural humanin levels and treatment with a manufactured peptide are separate questions.

What studies found. The included discovery studies found protection in neuronal cell systems involving Alzheimer-associated genes. Human genes or human-derived cells in an experiment do not make it a clinical treatment trial.

Risks and limitations. These studies do not show that administering humanin prevents dementia, restores memory or slows aging in people. Clinical effectiveness, appropriate treatment conditions and safety require direct human evidence, beyond an interesting cell-survival mechanism.

Sources

1. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta.
2. Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein.

Why people are interested. Icatibant is relevant to adults with hereditary angioedema who need treatment for an acute attack. It blocks a receptor for bradykinin, a signal involved in that type of swelling.

What it’s used or studied for. U.S. icatibant product labeling covers acute hereditary-angioedema attacks in adults age 18 and older. This does not make it a treatment for every cause of swelling.

What studies found. The FAST-1 and FAST-2 trials gave mixed main-outcome results: the active-comparator trial showed a significant benefit, while the placebo comparison did not meet statistical significance for its main endpoint.

Risks and limitations. Injection-site reactions were very common in product trials. Swelling involving the throat remains a medical emergency; the product label stresses appropriate medical care rather than relying on the medicine alone.

Sources

1. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
2. SAJAZIR current product labeling
3. FDA: ICATIBANT ACETATE approval history (selected product)

Why people are interested. Des(1–3)IGF-I interests researchers because removing a small part of insulin-like growth factor can change how it interacts with binding proteins.

What it’s used or studied for. Often called IGF-1 DES, this modified growth factor is different from the approved native IGF-I medicine mecasermin and from the longer LR3 analogue.

What studies found. The additional studies reviewed used rat cells and rats to investigate hormone secretion, distribution and clearance. They were not human treatment studies and do not establish human benefits.

Risks and limitations. Results in rats cannot establish a human duration of action, a safe regimen or improved muscle recovery. Approval of mecasermin does not transfer to this altered molecule, and laboratory potency is separate from clinical effectiveness.

Sources

1. The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF analogue, on growth hormone and IGF-binding protein secretion from cultured rat anterior pituitary cells.
2. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats.

Why people are interested. Long R3 IGF-I interests researchers because changes to the natural growth factor alter its interactions with binding proteins and receptors.

What it’s used or studied for. Also called IGF-1 LR3, it is an engineered analogue rather than native IGF-I. Researchers have examined its molecular behavior and distribution in animals.

What studies found. The additional evidence reviewed includes laboratory characterization and experiments in pregnant rats. It does not establish human absorption, duration of action, safety or treatment benefit.

Risks and limitations. Animal distribution and cellular activity cannot support a reliable human half-life or claims of muscle growth and recovery. It is also different from mecasermin and IGF-1 DES; evidence or approval for one molecule cannot establish the same for another.

Sources

1. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency.
2. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats.

Why people are interested. Insulin analogues matter when the body cannot make enough insulin or needs help maintaining safe blood sugar.

What it’s used or studied for. This is a family of medicines, including faster-acting and longer-acting products. Insulin glargine is one long-acting example used in diabetes care.

What studies found. Randomized studies in the Lantus label found blood-sugar improvement generally similar to NPH insulin across the studied diabetes populations. The result applies to that product and comparison, rather than every insulin analogue.

Risks and limitations. Insulin can cause dangerously low blood sugar, and products differ in how quickly and how long they act. It is not a bodybuilding or wellness supplement, and switching products requires careful clinical planning.

Sources

1. LANTUS (INSULIN GLARGINE) INJECTION, SOLUTION LANTUS SOLOSTAR (INSULIN GLARGINE) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]
2. FDA: SEMGLEE approval history

Why people are interested. Ipamorelin is of interest because it activates the ghrelin receptor, a signaling system connected with growth hormone release and digestive movement.

What it’s used or studied for. A human randomized trial tested intravenous ipamorelin after bowel surgery, hoping to speed recovery of normal eating and bowel function.

What studies found. The key eating-recovery outcome and secondary recovery outcomes did not differ significantly from placebo. The FDA assessment discusses this negative overall result and the limits of subgroup findings.

Risks and limitations. In the surgical trial, low potassium and high blood sugar were more frequent with ipamorelin. Surgery and underlying illness complicate interpretation. These findings do not establish the safety of injections under the skin, or demonstrate fat loss, muscle gain or general recovery benefits.

Sources

1. FDA: ipamorelin research and safety review (2024)
2. FDA UNII Y9M3S784Z6: Ipamorelin
3. Randomized trial of ipamorelin after bowel surgery

Why people are interested. Kisspeptin-10 interests researchers because it helps control reproductive-hormone signalling. Understanding that pathway could matter for future fertility treatments, but a hormonal response is only an early research step.

What it’s used or studied for. Small human studies examined how kisspeptin-10 changes luteinising hormone, a signal involved in reproductive function, and compared it with other hormone signals in healthy men.

What studies found. Researchers observed short-term increases and changes in hormone pulses. These experiments did not establish improved fertility, pregnancy rates or lasting symptom relief in patients.

Risks and limitations. Long-term safety and a treatment benefit remain unestablished by these studies. Kisspeptin-10 and kisspeptin-54 are different forms, and findings for one should not automatically be assigned to the other.

Sources

1. Kisspeptin-10 and luteinising-hormone pulse frequency in men
2. Direct comparison of kisspeptin-10, kisspeptin-54 and GnRH in healthy men

Why people are interested. KPV attracts research interest because it may influence inflammation without using the full-length hormone from which it is derived.

What it’s used or studied for. It is a three-amino-acid fragment of alpha-MSH, a hormone involved in several body signals. The included studies examine inflammation and fever in animals.

What studies found. The cited experiments found reduced ear swelling in mice and reduced fever in rabbits. They are not trials showing symptom relief in people.

Risks and limitations. An anti-inflammatory effect in an animal model does not establish that KPV treats human bowel disease, skin disease or another inflammatory condition. The potential benefit remains a research question, and human safety and effectiveness cannot be inferred from these experiments.

Sources

1. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH.
2. Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit.

Why people are interested. Lanreotide interests patients with certain neuroendocrine tumors because treatment may help keep disease stable for longer.

What it’s used or studied for. It mimics somatostatin, a hormone that slows some hormone-release signals. The included studies examine tumor control rather than general wellness or weight loss.

What studies found. A long-term extension study supported sustained tumor-control benefits in selected pancreatic and intestinal neuroendocrine tumors. An earlier randomized comparison found similar tumor-growth effects among the treatments tested, with modest response rates.

Risks and limitations. Extension studies can favor people who were already doing well enough to continue. Diarrhea was reported, and longer disease control does not mean that a tumor has been cured or that every tumor type responds.

Sources

1. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
2. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
3. FDA: LANREOTIDE ACETATE approval history (selected product)

Why people are interested. Larazotide interests people with celiac disease who continue to have symptoms despite following a gluten-free diet.

What it’s used or studied for. It is an experimental oral peptide intended to influence the barriers between intestinal cells. Researchers have studied persistent symptoms and responses to a controlled gluten challenge.

What studies found. Trials found improvement in some symptoms, but results were mixed. In one gluten-challenge study, a main test of intestinal permeability did not differ significantly from placebo.

Risks and limitations. It should not be presented as permission to eat gluten or as a replacement for a gluten-free diet. Symptom improvement and a proposed intestinal-barrier mechanism are different from demonstrating consistent control of celiac disease.

Sources

1. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.
2. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.

Why people are interested. Leuprolide is considered in advanced prostate cancer because reducing hormonal stimulation can help control the disease and its effects. This is a cancer-treatment goal, not a way to enhance normal hormone function.

What it’s used or studied for. NCI identifies leuprolide acetate as approved for palliative treatment of advanced prostate cancer. Palliative treatment aims to control disease effects and symptoms; it does not mean the medicine cures the cancer.

What studies found. Its established role is specific to that clinical context. Other leuprolide products or uses may have their own evidence and authorisations, which cannot be assumed from this cancer summary.

Risks and limitations. Treatment involves a substantial change in hormone signalling. The short NCI overview does not fully describe side effects or individual suitability.

Sources

1. Leuprolide acetate: NCI cancer-drug information
2. FDA: LEUPROLIDE ACETATE approval history

Why people are interested. Linaclotide is relevant to people whose constipation also causes abdominal discomfort or pain.

What it’s used or studied for. It acts mainly in the intestine to increase fluid movement and is studied in chronic constipation and irritable bowel syndrome with constipation.

What studies found. Randomized trials found improvements in bowel symptoms, and the irritable-bowel trial also found less abdominal pain over at least 12 weeks. These are direct patient-symptom outcomes rather than laboratory markers alone.

Risks and limitations. Diarrhea was the most common unwanted effect in the irritable-bowel trial and led 5.7% of linaclotide recipients to stop treatment, versus 0.3% with placebo. Longer-term benefits and risks need to be judged alongside the cause of constipation.

Sources

1. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
2. Two randomized trials of linaclotide for chronic constipation.
3. FDA: LINACLOTIDE approval history (selected product)

Why people are interested. Liraglutide interests people looking to improve type 2 diabetes control, particularly when weight is also a concern.

What it’s used or studied for. It mimics GLP-1, a hormone involved in blood sugar and appetite. Researchers have also examined it in fatty-liver inflammation.

What studies found. A diabetes trial found better average blood-sugar improvement than the exenatide regimen tested. A small liver trial found more resolution of inflammatory fatty-liver disease than placebo.

Risks and limitations. The liver study was an early trial and called for larger, longer studies. Results for a particular diabetes comparison cannot establish that liraglutide is the best option for everyone, or that it reliably reverses advanced liver scarring.

Sources

1. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
2. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
3. FDA: LIRAGLUTIDE approval history (selected product)

Why people are interested. Lixisenatide is relevant to type 2 diabetes treatment and to the development of medicines that target the GLP-1 pathway.

What it’s used or studied for. It was authorized as a blood-sugar medicine. A stand-alone product and a product combining it with insulin have separate treatment contexts.

What studies found. The regulator information confirms its historical diabetes indication. It does not establish a broad benefit for people without diabetes or a reason to choose it over every newer treatment.

Risks and limitations. The EU authorization for the stand-alone brand Lyxumia was withdrawn in December 2025 for commercial reasons. This is a product-and-region-specific change, not proof that every lixisenatide-containing medicine is unavailable worldwide.

Sources

1. EMA European public assessment report: Lyxumia
2. FDA: ADLYXIN approval history

Why people are interested. LL-37 interests researchers because it is part of the body’s natural defense against microbes and may help explain differences in susceptibility to infection.

What it’s used or studied for. It is a human antimicrobial peptide studied in skin tissue, cell experiments and animal infection models.

What studies found. A human skin study found lower levels in atopic dermatitis than in psoriasis. Laboratory work showed antibacterial activity, and experiments linked LL-37 to some antibacterial effects of stem-cell secretions.

Risks and limitations. Measuring a naturally occurring peptide is different from showing that administering it treats disease. These studies do not establish LL-37 as a safe treatment for eczema, infection or general immune support in people.

Sources

1. Endogenous antimicrobial peptides and skin infections in atopic dermatitis.
2. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37.

Why people are interested. LTX-315 interests cancer researchers because destroying tumor cells locally might also help the immune system recognize a tumor. That is a development goal, not proof of a cancer cure.

What it’s used or studied for. It is an experimental oncolytic peptide, meaning it is designed to damage cancer cells. The additional cited papers examined candidate selection and mechanisms of cell death.

What studies found. The cited evidence here is laboratory and tumor-model research, not a demonstration that patients live longer or that a cancer is cured. The work reported signals associated with immune-stimulating cell death.

Risks and limitations. Promising cell or tumor-model results do not establish benefit across cancers, human safety or an approved treatment. Clinical outcomes need to be evaluated separately for each study and cancer type.

Sources

1. The oncolytic peptide LTX-315 triggers immunogenic cell death.
2. Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide.

Why people are interested. Lutetium-177 dotatate is relevant to selected patients with neuroendocrine tumors when doctors want to deliver radiation directly to tumor-associated targets.

What it’s used or studied for. It combines a targeting peptide with a radioactive treatment. This is a cancer therapy, distinct from gallium-68 dotatate imaging.

What studies found. In a randomized trial analysis, patients receiving it took longer to experience worsening in overall health, physical function and several symptoms than patients receiving high-dose octreotide.

Risks and limitations. The treatment requires specialist assessment and monitoring. Kidney-radiation research highlights the importance of individual risk factors. Benefits shown in progressive midgut neuroendocrine tumors do not automatically apply to every cancer, and improved quality of life does not establish cure.

Sources

1. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With ¹⁷⁷Lu-Dotatate in the Phase III NETTER-1 Trial.
2. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.
3. FDA: BEXLUTRY approval history (selected product)

Why people are interested. Lutetium Lu-177 vipivotide tetraxetan, sold as Pluvicto, is considered for particular prostate cancers because it delivers radiation to cells carrying a target called PSMA. It is a specialist cancer medicine.

What it’s used or studied for. FDA's July 2026 notice covers its combination with androgen-receptor-pathway treatment in a specifically defined group with PSMA-positive prostate cancer that has spread.

What studies found. In the 1,144-person PSMAddition trial, adding Pluvicto delayed worsening seen on scans compared with the hormone-pathway treatment alone. Overall survival results were not mature at that analysis.

Risks and limitations. Risks include radiation exposure, reduced blood-cell production, kidney damage and infertility. A scan-based benefit is not yet proof that this particular combination makes patients live longer.

Sources

1. FDA approval of Pluvicto with androgen-receptor-pathway inhibitor therapy, July 31, 2026
2. FDA: PLUVICTO approval history

Why people are interested. Mazdutide attracts interest for weight reduction through a combination of appetite-related and metabolic hormone pathways.

What it’s used or studied for. It activates GLP-1 and glucagon receptors. The included trials involved Chinese adults with overweight or obesity.

What studies found. In a 24-week randomized trial, average weight loss ranged from roughly 7% to 11% across treatment groups, compared with a small weight increase with placebo.

Risks and limitations. Diarrhea and nausea were among the common unwanted effects. Results from a defined population and limited follow-up do not settle long-term outcomes or predict an individual response. Regulatory availability also depends on country and cannot be inferred from publication of a successful trial.

Sources

1. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.
2. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

Why people are interested. Mecasermin is relevant to children whose poor growth results from severe deficiency of IGF-1, a hormone needed for normal growth.

What it’s used or studied for. It replaces IGF-1 in a narrowly defined medical condition. It is not the same as giving growth hormone and is not a general height or muscle supplement.

What studies found. In studies of children with severe deficiency, average growth increased from 2.8 cm per year before treatment to 8.0 cm in the first year. Most studies did not include a comparison treatment, which limits certainty about the size of benefit.

Risks and limitations. Low blood sugar, headache and vomiting are common reported effects, and treatment is restricted in active abnormal cell growth. Benefits in severe deficiency do not establish safe bodybuilding, anti-aging or general enhancement use.

Sources

1. EMA European public assessment report: Increlex
2. FDA: Increlex approval history
3. DailyMed INCRELEX (MECASERMIN) INJECTION [ETON PHARMACEUTICALS, INC.]

Why people are interested. Mechano growth factor is relevant to muscle research because the body can change expression of certain IGF-I gene variants after growth-related signals.

What it’s used or studied for. The name describes splice-variant and protein-fragment biology. Products labeled MGF or PEG-MGF do not necessarily represent the same precisely defined substance.

What studies found. A human muscle-biopsy study measured gene expression after growth hormone and resistance training; it did not administer MGF. A separate mouse study also measured expression after altered growth-hormone signaling.

Risks and limitations. These findings do not establish that injected MGF repairs injuries, builds muscle or improves performance in people. Measuring the body’s own gene activity is different from testing an administered product, and animal findings remain separate from human outcomes.

Sources

1. The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men.
2. Muscle mechano growth factor is preferentially induced by growth hormone in growth hormone-deficient lit/lit mice

Why people are interested. Melanotan-I appears in older pigmentation research, which can make the name attractive to someone looking for a tan. Its medicinal history should not be confused with the quality or purpose of an internet product.

What it’s used or studied for. It is a historical name associated with afamelanotide. The approved SCENESSE implant has a specific role in adults with erythropoietic protoporphyria, a rare condition causing painful reactions to light.

What studies found. Older, very small volunteer studies reported increased pigmentation and measured how experimental formulations moved through the body. Those findings were not trials establishing a safe consumer tanning product.

Risks and limitations. Formulation and route matter. SCENESSE can darken existing moles and freckles and carries hypersensitivity warnings; a product labeled Melanotan-I is not automatically equivalent to that approved implant.

Sources

1. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans.
2. Skin pigmentation and pharmacokinetics of melanotan-I in humans.
3. SCENESSE current product labeling
4. FDA: SCENESSE approval history (selected product)

Why people are interested. Melanotan II draws attention around skin pigmentation and sexual response because it activates melanocortin receptors. Those biological effects have also led to potentially risky use of unverified products.

What it’s used or studied for. It was examined in small early human sexual-function experiments. It is distinct from both afamelanotide and the approved bremelanotide product, even though the names are sometimes discussed together.

What studies found. A small crossover study in men reported erectile responses and increased reported desire, but also nausea. That does not establish a general-purpose sexual medicine or the safety of cosmetic tanning use.

Risks and limitations. A published case report documented severe systemic toxicity, muscle breakdown and kidney dysfunction after an internet-purchased product. One case cannot estimate frequency, but it is an important warning against assuming safety.

Sources

1. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.
2. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.

Why people are interested. Ibutamoren, also called MK-677, interests researchers because it stimulates a receptor linked to growth hormone release and appetite.

What it’s used or studied for. It has been investigated for several conditions, including growth hormone deficiency, muscle loss and recovery after hip fracture. It is a small molecule, not a peptide or a SARM.

What studies found. The FDA review found insufficient evidence of meaningful clinical benefit for the proposed uses. Changes in hormone levels or lean mass alone did not establish improved function or recovery.

Risks and limitations. FDA identifies ibutamoren as unapproved and warns about fluid retention, altered glucose control and possible heart-failure risk in some people. Long-term effects remain uncertain.

Sources

1. FDA October 2024 PCAC scientific assessment: ibutamoren mesylate
2. FDA: Agebox iKids Growth Day Formula may be harmful due to hidden ingredient

Why people are interested. Motixafortide helps solve a practical problem before a stem-cell transplant: collecting enough of a patient's own blood-forming stem cells. Its benefit is preparation for treatment, rather than directly curing the cancer.

What it’s used or studied for. Aphexda is used with filgrastim in adults with multiple myeloma, a cancer of certain immune cells, before a transplant using their own cells.

What studies found. In the 122-person GENESIS trial, 67.5% receiving the combination reached the specified collection target within two collection sessions, compared with 9.5% receiving placebo plus filgrastim.

Risks and limitations. Injection-site reactions, itching, flushing and rash were common. The collection result does not by itself show better cancer survival or establish benefits in other cancers.

Sources

1. Drug Trials Snapshots: APHEXDA
2. FDA: APHEXDA approval history

Why people are interested. MOTS-c interests researchers studying how cells respond to metabolic stress and how mitochondria communicate with the rest of the cell.

What it’s used or studied for. It is a mitochondrial-derived research peptide, discussed in connection with metabolism, exercise and aging.

What studies found. The included laboratory study examines how cells respond to stress, not whether treatment improves health in people. The FDA assessment identifies major gaps in what happens when manufactured MOTS-c is given to people, including how the body absorbs and clears it and whether it is safe.

Risks and limitations. Research on naturally occurring MOTS-c is different from showing that administering a manufactured product improves health. Conditional compounding policy is also separate from FDA approval and evidence of benefit. Human anti-aging or exercise benefits remain unestablished by these sources.

Sources

1. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.
2. FDA July 2026 PCAC scientific assessment: MOTS-c
3. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances
4. HHS notice of availability: FR Doc 2026-22192

Why people are interested. Murepavadin interests researchers seeking more targeted treatments for serious infections caused by Pseudomonas bacteria.

What it’s used or studied for. It is an experimental antibiotic that interferes with an essential part of the bacterial outer membrane.

What studies found. The included human study examined drug exposure and tolerability, not whether infections were cured. People with reduced kidney function had higher and longer-lasting exposure to the medicine. Laboratory research helps explain its bacterial target.

Risks and limitations. Understanding how a medicine behaves in the body is necessary, but it is not proof that it improves survival or clears infection. Kidney-function differences matter, and clinical efficacy and the overall safety balance need separate evidence.

Sources

1. Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment.
2. A Peptidomimetic Antibiotic Interacts with the Periplasmic Domain of LptD from Pseudomonas aeruginosa.

Why people are interested. Nafarelin is considered when lowering certain reproductive hormones can address endometriosis or puberty that starts too early. These are different diagnosed conditions, rather than general reasons to suppress hormones.

What it’s used or studied for. The nasal medicine is used to manage endometriosis, where tissue similar to the womb lining grows elsewhere, and central precocious puberty in children.

What studies found. Its established clinical purpose is to reduce hormone stimulation relevant to those conditions. That does not mean it cures infertility or benefits people with normal hormone function.

Risks and limitations. Hot flushes, mood changes, headaches and nasal irritation can occur. Bone density can fall, increasing fracture concerns, and early puberty signs may initially worsen in children.

Sources

1. Nafarelin Nasal Spray – MedlinePlus Drug Information
2. FDA: SYNAREL approval history

Why people are interested. Nangibotide interests researchers trying to reduce the damaging immune response that can accompany septic shock, a life-threatening reaction to infection.

What it’s used or studied for. It targets the TREM-1 immune-signaling pathway and has been studied in healthy volunteers and hospitalized patients with septic shock.

What studies found. An early trial in 49 patients found no significant increase in reported adverse events compared with placebo, but it also did not show significant improvement in the measured disease-response outcomes.

Risks and limitations. A small early trial cannot establish survival benefit or rule out uncommon harms. Findings that justify more research should not be described as proof that the medicine treats sepsis successfully or helps general immune health.

Sources

1. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
2. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.

Why people are interested. Nesiritide attracted interest as a hospital treatment for worsening heart failure, aiming to ease the pressure burden on a struggling heart. It is a manufactured version of a hormone the body produces.

What it’s used or studied for. Historical studies examined intravenous nesiritide in symptomatic decompensated heart failure, meaning heart failure that has worsened enough to require urgent treatment.

What studies found. A 103-person trial found improvements in heart and circulation measurements during a 24-hour infusion. These short-term measurements did not establish longer survival or lasting improvement.

Risks and limitations. Natrecor's FDA approval was withdrawn effective June 15, 2020 after its manufacturer reported that it was no longer marketed. That withdrawal should not be described as a proven safety ban.

Sources

1. Nesiritide in heart failure: randomised placebo-controlled haemodynamic trial, 1999
2. FDA withdrawal of 16 new drug applications: Federal Register, May 14, 2020

Why people are interested. NNZ-2591 interests researchers and families affected by rare developmental conditions because a treatment that improves communication, behavior or daily function could make a practical difference.

What it’s used or studied for. It is an experimental small cyclic compound related to glycine and proline. Human research has included children with Phelan-McDermid syndrome, alongside earlier animal studies of brain injury and memory.

What studies found. An open-label study in 18 children reported improvements from the starting measurements on several clinician and caregiver assessments. There was no placebo group, so the study cannot establish how much improvement was caused by the medicine.

Risks and limitations. Most health problems reported during that small study were mild to moderate, but its size and design leave uncertainty about effectiveness and less common or long-term harms. Larger controlled studies are needed.

Sources

1. Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats.
2. NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat.
3. NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome: Single-Group, Open-Label, Phase 2 Trial Results.

Why people are interested. Nonapeptide-1 is of interest in products addressing uneven pigmentation. The clinically important question is whether a product improves the appearance of the relevant skin condition, rather than only changing a laboratory signal.

What it’s used or studied for. The cited research includes a multi-ingredient melasma-maintenance product and an experimental delivery system containing green-tea-derived EGCG and nonapeptide-1.

What studies found. In a small pilot involving 46 people, the combination group improved on some measures, but reported between-group differences in severity and pigment measurements were not statistically significant. The ingredient’s individual contribution was not isolated.

Risks and limitations. Combination results cannot establish that nonapeptide-1 alone treats melasma. Laboratory delivery-system findings also do not prove visible benefits, safety or effectiveness of a commercial skincare product.

Sources

1. A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance.
2. Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging.

Why people are interested. Octreotide can interest people with acromegaly, a condition in which too much growth hormone causes changes in the body and significant health problems.

What it’s used or studied for. It reduces hormone-release signals. The included studies compare oral and injectable treatment and examine medical treatment alongside surgery.

What studies found. In selected patients already controlled on injectable treatment, oral octreotide maintained control at a comparable level. A separate comparison found better surgical success at 24 weeks, while the difference at 48 weeks was not statistically significant.

Risks and limitations. The findings do not make tablets, injections and surgery interchangeable for every patient. Existing response, tumor characteristics and specialist assessment affect the choice and the chance of controlling hormone levels.

Sources

1. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
2. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
3. FDA: BYNFEZIA PEN approval history (selected product)

Why people are interested. Oligopeptide-1 is a name worth clarifying before buying skincare or interpreting a study. Similar-looking ingredient names can refer to different materials, especially when growth-factor claims are involved.

What it’s used or studied for. The name sh-Oligopeptide-1 is associated with recombinant human epidermal growth factor, or EGF. A bare oligopeptide-1 listing does not, by itself, establish that it is the same material.

What studies found. A small human study investigated EGF in a particular hyaluronic-acid microneedle patch and reported wrinkle improvements. It did not test every ingredient or product marketed under the bare oligopeptide-1 name.

Risks and limitations. If the identity differs, the study may not apply. The formulation, actual ingredient and delivery system need to match before a reported result can be used to support a product claim.

Sources

1. Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin.
2. PubChem: SH-Oligopeptide-1 (rh-EGF)

Why people are interested. Oxytocin has an important medical role after childbirth: helping the womb contract to reduce the risk of excessive bleeding. That benefit is more specific than popular claims about bonding or wellbeing.

What it’s used or studied for. WHO includes oxytocin in guidance on medicines that prevent postpartum haemorrhage, meaning dangerous bleeding after birth. These medicines are called uterotonics because they stimulate womb contractions.

What studies found. The supported human benefit here is prevention of bleeding in maternity care. The cited guidance does not establish that consumer oxytocin products improve relationships, sexual wellbeing or general mood.

Risks and limitations. Its effects depend on the obstetric setting, formulation and clinical oversight. A recognised role in childbirth is not evidence that unsupervised or unrelated use is beneficial.

Sources

1. WHO recommendations: uterotonics for prevention of postpartum haemorrhage
2. FDA: OXYTOCIN approval history

Why people are interested. Palmitoyl hexapeptide-12 appears in cosmetic research on skin-conditioning ingredients. A reader may be interested in whether that translates into a visible improvement, but safety assessment and effectiveness are different questions.

What it’s used or studied for. It is a peptide with a fatty-acid attachment. The cited expert-panel assessment considered specific peptide sequences and cosmetic-use practices, rather than treating every similarly named material as identical.

What studies found. The additional sources here establish identity and discuss cosmetic safety. They do not report a human trial showing that the ingredient itself makes wrinkles less visible or skin firmer.

Risks and limitations. The panel’s conclusion was limited to the uses and concentrations it assessed. It does not establish effectiveness, approval as a medicine, or safety when injected or used systemically.

Sources

1. PubChem compound 10212452: Palmitoyl Hexapeptide-12
2. Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics

Why people are interested. The interest is whether a topical product can make fine lines, such as crow’s feet, less visible. Palmitoyl pentapeptide-4 is one cosmetic ingredient investigated for that purpose.

What it’s used or studied for. The peptide has a fatty-acid attachment, which is part of its identity. The cited work tested both a cream in people and a specialized delivery system in laboratory and animal experiments.

What studies found. A small randomized study in 21 Indonesian women reported better results for the peptide cream on some appearance measures compared with the other study groups. The authors called for larger, longer studies.

Risks and limitations. The small sample limits confidence in how broadly the result applies. Results from a specialized formulation or an animal experiment cannot establish the performance of every cosmetic containing the ingredient.

Sources

1. Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet.
2. Bioactive Glycyrrhizic Acid Ionic Liquid Self-Assembled Nanomicelles for Enhanced Transdermal Delivery of Anti-Photoaging Signal Peptides.

Why people are interested. Palmitoyl tetrapeptide-7 is investigated in skincare blends aimed at improving the appearance and condition of aging skin. Whether a person sees a difference depends on the formulation actually tested.

What it’s used or studied for. The cited studies examined peptide blends using skin-imaging methods and a multi-component eye cream containing several active ingredients.

What studies found. The studies reported improvements in measures of skin structure or in hydration, elasticity and appearance during product use. They did not separate the effect of palmitoyl tetrapeptide-7 from the other ingredients.

Risks and limitations. The findings therefore belong to the tested combinations. They cannot show that every product containing this peptide works, or that the ingredient alone produces the reported changes.

Sources

1. Evaluation of dermal extracellular matrix and epidermal-dermal junction modifications using matrix-assisted laser desorption/ionization mass spectrometric imaging, in vivo reflectance confocal microscopy, echography, and histology: effect of age and peptide applications.
2. Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream.

Why people are interested. Palmitoyl tripeptide-1, also called Pal-GHK, attracts interest in skincare because of research connected with collagen and skin appearance. That interest needs to be separated from what has actually been demonstrated in people.

What it’s used or studied for. One cited study examined where the ingredient reached in the outer skin layers. Another investigated a combined skincare regimen containing both this peptide and baicalin.

What studies found. A small study involving 30 women reported improvements in appearance and firmness measures with the combined regimen. The permeation study showed distribution in the outer skin, which is not itself proof of benefit.

Risks and limitations. Neither finding establishes the peptide’s isolated clinical effect. A combination regimen and a few-person distribution experiment cannot predict the performance of every formulation containing Pal-GHK.

Sources

1. Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism.
2. Permeation behaviour of cosmetic actives into the human stratum corneum.

Why people are interested. Palmitoyl tripeptide-38 is of interest as part of skincare intended to improve visible signs of aging, such as fine lines or skin texture. The evidence concerns actual products, not just a promising ingredient name.

What it’s used or studied for. The cited studies evaluated multi-ingredient serums or moisturizers containing the peptide alongside other substances, including plant-derived ingredients or vitamins.

What studies found. Small human product studies reported improvements in several skin-appearance measures compared with participants’ starting measurements. One was explicitly open-label, meaning participants and investigators knew the product being used.

Risks and limitations. Without isolating the ingredient or reliably separating product effects from other changes, these studies cannot establish how much benefit came from this peptide. The results do not apply automatically to other products.

Sources

1. Biorevitalizing effect of a novel facial serum containing apple stem cell extract, pro-collagen lipopeptide, creatine, and urea on skin aging signs.
2. An Open Label Clinical Trial of a Multi-Ingredient Anti-Aging Moisturizer Designed to Improve the Appearance of Facial Skin.

Why people are interested. People with chronic hypoparathyroidism cannot produce enough parathyroid hormone, making normal calcium control difficult and often requiring substantial supplement treatment.

What it’s used or studied for. Palopegteriparatide, sold as Yorvipath, releases a hormone fragment that replaces part of this missing signaling. It is approved for adults with chronic hypoparathyroidism.

What studies found. In an eighty-four-person study summarized by the EMA, substantially more treated participants maintained normal calcium without their usual active vitamin D and high-dose calcium treatment than participants receiving placebo.

Risks and limitations. The findings concern diagnosed hormone deficiency, not general wellness. Injection-site reactions, headache and unusual sensations such as pins and needles were common. The medicine is unsuitable for a related condition in which tissues do not respond properly to parathyroid hormone.

Sources

1. EMA European public assessment report: Yorvipath
2. FDA: Yorvipath approval history
3. DailyMed: Yorvipath prescribing information

Why people are interested. Parathyroid hormone helps regulate blood calcium, so replacing a deficiency can address a specific endocrine disorder rather than simply adding another calcium supplement.

What it’s used or studied for. Full-length replacement hormone, including the former Natpar product, must be distinguished from shorter fragments such as teriparatide and from medicines that release those fragments.

What studies found. FDA approval history establishes a specific replacement product. It does not show that every product carrying the parathyroid-hormone name has the same clinical effects or evidence.

Risks and limitations. Availability is an important practical limitation: the EMA reports Natpar’s European authorization was withdrawn in July 2026 because of supply issues. Historical approval is separate from current access, and findings cannot be transferred between different hormone products.

Sources

1. EMA European public assessment report: Natpar
2. FDA: NATPARA approval history

Why people are interested. Pasireotide is relevant when excess hormone production causes Cushing disease or acromegaly and other treatments are unsuitable or insufficient.

What it’s used or studied for. It reduces hormone-release signals. The particular formulation and indication matter because the treatment goals differ between these diseases.

What studies found. Human trials found normalization or reduction of excess cortisol in some Cushing-disease patients and improvement in growth-hormone-related measures in some patients with acromegaly. Many patients did not achieve the target response.

Risks and limitations. High blood sugar and diabetes are important risks; diarrhea, abdominal pain and gallstones also occur. It should not be described as general hormone optimization, and benefit needs to be balanced against disease-specific risks.

Sources

1. EMA European public assessment report: Signifor
2. FDA: SIGNIFOR approval history
3. DailyMed SIGNIFOR (PASIREOTIDE) INJECTION [RECORDATI RARE DISEASES, INC.]

Why people are interested. Pegcetacoplan is considered when an overactive part of the immune system, called complement, damages blood cells or kidney tissue. The treatment aims to reduce that specific damage.

What it’s used or studied for. EMA describes Aspaveli for paroxysmal nocturnal haemoglobinuria, or PNH, and specified complement-related kidney diseases. In PNH, red blood cells break down too quickly and can cause anaemia.

What studies found. In an 80-person PNH study, patients switched to Aspaveli had higher haemoglobin levels and needed fewer transfusions than those continuing eculizumab. These findings apply to the studied PNH population.

Risks and limitations. Blocking complement increases important infection risks. Systemic Aspaveli and eye formulations are different treatments; evidence for one cannot simply establish the benefits or safety of another.

Sources

1. Aspaveli – EMA public assessment report
2. FDA: EMPAVELI approval history

Why people are interested. Pegvisomant is relevant to people with acromegaly whose excess growth-hormone activity remains inadequately controlled.

What it’s used or studied for. It blocks growth-hormone receptors, rather than stimulating growth hormone. Treatment aims to bring IGF-1, a hormone downstream of growth hormone, into the normal range.

What studies found. In the regulator-reviewed 12-week study, IGF-1 normalized more often with pegvisomant than placebo, with results varying across treatment groups.

Risks and limitations. Headache, diarrhea and joint pain are common reported effects. Hormone normalization is a meaningful treatment goal but does not establish cure or eliminate the need for specialist follow-up. This is not an enhancement medicine for healthy adults.

Sources

1. EMA European public assessment report: Somavert
2. FDA: Somavert approval history
3. DailyMed SOMAVERT (PEGVISOMANT) KIT [PHARMACIA & UPJOHN COMPANY LLC]

Why people are interested. Pemvidutide attracts interest for reducing excess liver fat as well as body weight in people with metabolic liver disease.

What it’s used or studied for. It activates GLP-1 and glucagon pathways and has been studied in people with metabolic dysfunction-associated steatotic liver disease, commonly called fatty liver disease.

What studies found. A randomized trial found greater reductions in liver fat, markers of liver inflammation and body weight than placebo.

Risks and limitations. Less liver fat is encouraging, but it does not by itself prove prevention of cirrhosis or longer survival. The linked registration and research paper describe the same trial. Longer-term outcomes, side effects and current treatment availability require separate assessment.

Sources

1. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
2. ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Why people are interested. Pentapeptide-18, also associated with the name Leuphasyl, is investigated in cosmetic formulation research. A reader may be interested in wrinkle-related claims, but the material tested and the outcome measured matter.

What it’s used or studied for. The additional cited work examined a modified version with an added D-tyrosine and a formulation combining peptide with retinol in lipid nanoparticles.

What studies found. These studies did not demonstrate wrinkle reduction in people. One reported laboratory changes related to pigment production with the modified peptide; the other studied the formulation’s physical properties and stability.

Risks and limitations. A modified molecule is not identical to the original ingredient. Improved formulation stability is useful development work, but does not prove a cosmetic benefit, clinical safety or the effect of a finished product.

Sources

1. D-tyrosine adds an anti-melanogenic effect to cosmetic peptides.
2. Solid Lipid Nanoparticles Incorporated with Retinol and Pentapeptide-18-Optimization, Characterization, and Cosmetic Application.

Why people are interested. Petrelintide interests researchers seeking another way to support weight management, potentially with a different tolerability profile from existing medicines.

What it’s used or studied for. It is a long-acting version of amylin, a natural hormone involved in feeling full after eating.

What studies found. Two early randomized human studies reported clinically relevant weight loss and relatively few gastrointestinal adverse events. The results supported further clinical development.

Risks and limitations. Early studies cannot establish that it is safer or more effective than established medicines in everyday care. The suggestion of improved stomach-and-bowel tolerability needs direct confirmation, and larger, longer trials are needed to establish durable benefits and detect less common unwanted effects.

Sources

1. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.
2. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.

Why people are interested. Plecanatide is of interest when constipation and abdominal discomfort interfere with daily life.

What it’s used or studied for. It acts in the intestine through a pathway that increases fluid secretion. The included research includes irritable bowel syndrome with constipation and early human pharmacology.

What studies found. Phase 3 trials found improvement in both constipation symptoms and abdominal pain compared with placebo. An early volunteer study found little measurable movement of the medicine into the bloodstream.

Risks and limitations. Diarrhea was the most common unwanted effect in the phase 3 trials, reported by about 4% with plecanatide versus 1% with placebo. Limited bloodstream exposure does not mean unwanted effects are impossible, and not everyone experienced meaningful symptom relief.

Sources

1. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
2. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses.
3. FDA: TRULANCE approval history (selected product)

Why people are interested. PN-943 interests researchers looking for an oral treatment that targets intestinal inflammation while limiting exposure elsewhere in the body.

What it’s used or studied for. It targets an integrin pathway involved in immune-cell movement and has been studied for ulcerative colitis, an inflammatory disease of the colon.

What studies found. A healthy-volunteer study found low bloodstream exposure and evidence that the drug engaged its intended target. A separate phase 2 ulcerative-colitis trial is listed as completed, without posted results in the cited registration.

Risks and limitations. Target engagement is not proof that symptoms or inflammation improve. The included human evidence does not establish a successful ulcerative-colitis treatment or justify replacing existing care.

Sources

1. Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers.
2. PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Why people are interested. Polymyxin B and colistin matter mainly in specialist treatment of serious bacterial infections when resistance limits other options.

What it’s used or studied for. They are related antibiotics but are not interchangeable names for one medicine. The included sources cover polymyxin B drug-handling research and a trial using colistin as a comparison treatment.

What studies found. In the infection trial, a newer antibiotic combination met the study’s criterion for comparable survival outcomes to colistin. The polymyxin B study helped characterize how the medicine behaves in seriously ill patients.

Risks and limitations. Kidney toxicity occurred in 38% of the colistin group versus 13% with the newer combination in that trial. This does not describe every use of either antibiotic. Infection type, the exact medicine and close clinical monitoring matter.

Sources

1. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
2. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).

Why people are interested. Pramlintide can be relevant when mealtime insulin alone is not achieving the desired diabetes control.

What it’s used or studied for. It mimics amylin, a hormone that helps regulate blood sugar after meals, and is used alongside insulin in selected patients.

What studies found. A randomized type 1 diabetes trial found smaller after-meal blood-sugar rises and lower weight with pramlintide. Average long-term blood-sugar improvement was similar between the treatment and placebo groups.

Risks and limitations. The US label carries a boxed warning for severe low blood sugar when combined with insulin, particularly in type 1 diabetes. Benefits require careful treatment planning; it does not replace insulin or make unsupervised insulin changes safe.

Sources

1. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
2. FDA: SYMLIN approval history
3. SYMLINPEN (PRAMLINTIDE ACETATE) INJECTION [ASTRAZENECA PHARMACEUTICALS LP]

Why people are interested. PT-141 is a development name for bremelanotide, so the interest is connected to sexual desire and arousal rather than a separate class of treatment.

What it’s used or studied for. The approved bremelanotide product, Vyleesi, has a limited U.S. indication for certain premenopausal women with distressing acquired, generalized low sexual desire. Its label does not endorse sexual-performance enhancement.

What studies found. Early human studies reported some sexual-response effects, but they involved experimental formulations and selected populations. Those results do not establish that every product sold as PT-141 performs like Vyleesi.

Risks and limitations. The approved product can cause nausea, temporary blood-pressure changes and skin darkening. A familiar ingredient name does not verify the identity, purity or formulation of an unverified product.

Sources

1. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
2. PT-141: a melanocortin agonist for the treatment of sexual dysfunction.
3. Vyleesi current product labeling
4. FDA: VYLEESI (AUTOINJECTOR) approval history (selected product)

Why people are interested. Retatrutide draws attention for potentially substantial weight loss while also improving blood sugar.

What it’s used or studied for. It is an experimental medicine that activates three hormone pathways: GIP, GLP-1 and glucagon. The included studies involve adults with type 2 diabetes.

What studies found. A phase 2 trial found meaningful improvements in blood sugar and body weight. A body-composition analysis found more body-fat reduction than placebo or dulaglutide.

Risks and limitations. Stomach-and-bowel adverse events affected 35% of retatrutide recipients versus 13% with placebo in the main trial. Some weight lost was lean tissue. The body-composition analysis is not an independent trial, and long-term safety remains a separate question.

Sources

1. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
2. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
3. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

Why people are interested. Rusfertide may interest adults with polycythaemia vera who need repeated blood-removal procedures to control excess red blood cells. The hoped-for practical benefit is reducing that treatment burden.

What it’s used or studied for. FDA approved Mimrylo in August 2026 for adults with this blood disorder. It mimics hepcidin, a hormone that controls how much iron is available for making red blood cells.

What studies found. The supporting trial included 293 adults needing frequent blood removal despite standard treatment. Rusfertide helped substantially more patients avoid meeting the need for further procedures during the trial's assessment period than placebo.

Risks and limitations. Injection-site reactions and anaemia were common. This disease-specific benefit does not support manipulating iron for athletic performance or general longevity.

Sources

1. FDA approval of Mimrylo (rusfertide) for polycythaemia vera, August 28, 2026
2. FDA: MIMRYLO approval history

Why people are interested. Secretin can help doctors investigate pancreatic function and certain hormone-secreting tumors.

What it’s used or studied for. Synthetic human secretin stimulates digestive secretions during diagnostic procedures. Its value is in helping a test answer a medical question, rather than treating everyday indigestion.

What studies found. The included small human study compared methods of collecting pancreatic fluid after stimulation. It assessed diagnostic agreement, not relief of symptoms or treatment of disease.

Risks and limitations. Some liver conditions can alter the response and mask pancreatic disease, according to the label. Results therefore need interpretation alongside other clinical information. Diagnostic authorization does not establish benefit as a general digestive supplement or treatment for unrelated conditions.

Sources

1. A randomized crossover study of secretin-stimulated endoscopic and dreiling tube pancreatic function test methods in healthy subjects.
2. FDA: CHIRHOSTIM approval history
3. CHIRHOSTIM (HUMAN SECRETIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION CHIRHOSTIM 40 (HUMAN SECRETIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [CHIRHOCLIN, INC.]

Why people are interested. Selank interests researchers studying stress responses and anxiety-related biology. For an individual reader, the practical question is whether it improves symptoms in people, not only animal behavior.

What it’s used or studied for. It is a peptide related to tuftsin. The cited work examined responses to stressful situations in rodents and how the peptide and related fragments break down in laboratory experiments.

What studies found. These sources do not show clinical anxiety treatment outcomes. Rodent behavior changed in one study; the other described peptide breakdown rather than a benefit patients could feel.

Risks and limitations. Those findings do not establish how well it works in people or its longer-term safety. A laboratory description calling a compound anxiolytic is not the same as evidence of an approved anxiety medicine.

Sources

1. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.
2. [Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation].

Why people are interested. Selepressin was designed to raise blood pressure in septic shock while targeting a particular vasopressin receptor. Researchers hoped this selectivity might help circulation with fewer unwanted effects.

What it’s used or studied for. Early human research explored blood-pressure support in septic shock. The later SEPSIS-ACT trial tested whether adding selepressin to standard care helped critically ill adults spend more days alive without breathing machines or blood-pressure medicines.

What studies found. SEPSIS-ACT analysed 828 treated patients and found no significant improvement in that main outcome or 90-day mortality. It stopped early for futility, meaning the results did not justify continuing toward the planned benefit.

Risks and limitations. The larger negative trial limits the meaning of earlier encouraging blood-pressure findings. A small earlier trial also stopped one higher-exposure group after a possible safety concern.

Sources

1. Selepressin: a phase IIa randomised trial in septic shock
2. Selepressin in an ovine septic-shock model
3. Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial

Why people are interested. Semaglutide is known for helping eligible people lose weight. Its medical uses depend on the particular product and formulation, rather than the ingredient name alone.

What it’s used or studied for. Wegovy is used with dietary changes and physical activity for long-term weight management in specified patients. Certain Wegovy formulations also have approved heart-risk or liver-disease uses.

What studies found. In STEP 1, 1,961 adults with obesity or overweight and a related condition, without diabetes, received semaglutide or placebo alongside lifestyle support. Average weight loss at 68 weeks was 14.9% versus 2.4%. Results vary between people.

Risks and limitations. Nausea, diarrhea and vomiting are common. Label warnings include pancreatitis, gallbladder problems and dehydration-related kidney injury. Wegovy must not be used with a personal or family history of medullary thyroid cancer or the inherited condition MEN 2.

Sources

1. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
2. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
3. FDA: Wegovy tablets approval history (selected product)
4. Wegovy current U.S. prescribing information, revised June 2026
5. Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Why people are interested. Semax attracts interest around recovery after brain injury and questions about memory because research has examined nerve-growth signals and functional recovery. Those are different questions from boosting everyday performance in healthy people.

What it’s used or studied for. It is an analogue of a fragment of adrenocorticotropic hormone. Studies have examined rat brain signaling and its use alongside rehabilitation after ischemic stroke in people.

What studies found. A study involving 110 stroke patients reported faster improvement in a measure of daily function in the Semax groups. That finding concerns stroke rehabilitation and does not establish better memory or attention in otherwise healthy people.

Risks and limitations. The selected evidence does not settle general effectiveness or long-term safety. The dated October 2026 HHS draft policy discusses conditional compounding enforcement; it is not FDA approval of a cognitive treatment.

Sources

1. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog.
2. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.
3. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke].

Why people are interested. Sermorelin copies part of the body’s signal that tells the pituitary gland to release growth hormone. Its established history concerns evaluating growth-hormone release and treating a specific childhood growth disorder.

What it’s used or studied for. Historical GEREF products were approved to evaluate the pituitary gland’s ability to release growth hormone, and to treat unexplained growth hormone deficiency in children with growth failure.

What studies found. Those narrow medical uses are different from claims about energy, muscle building or slowing aging in otherwise healthy adults. The historical approvals do not establish those adult wellness benefits.

Risks and limitations. GEREF products were discontinued. FDA determined in 2013 that they had not been withdrawn from sale for safety or effectiveness reasons. That finding does not make today’s compounded sermorelin preparations FDA-approved or establish their benefit for another purpose.

Sources

1. FDA UNII 89243S03TE: Sermorelin
2. FDA: GEREF approval history
3. FDA determination concerning discontinued GEREF products, Federal Register, 4 March 2013

Why people are interested. Setmelanotide can matter to people with rare inherited conditions that cause severe, persistent hunger and early-onset obesity.

What it’s used or studied for. It activates a brain pathway involved in hunger regulation. The included studies involve specific POMC or leptin-receptor deficiencies, not ordinary weight gain.

What studies found. Very small early studies reported substantial reductions in hunger and body weight in two people with POMC deficiency and three with leptin-receptor deficiency.

Risks and limitations. These findings are important for narrowly defined genetic conditions, but such tiny studies cannot predict results for the general population. A diagnosis and appropriate genetic assessment are central to understanding whether the research is relevant to an individual.

Sources

1. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.
2. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
3. FDA: IMCIVREE approval history (selected product)

Why people are interested. Sincalide is relevant when doctors need to investigate how well the gallbladder empties, rather than to improve everyday digestion.

What it’s used or studied for. It stimulates gallbladder contraction during a diagnostic scan, helping clinicians measure the proportion of bile released.

What studies found. Healthy-volunteer studies showed that the way sincalide is administered can strongly affect the test result. Slower administration produced more consistent normal values than short administration in the included comparisons.

Risks and limitations. This is a diagnostic tool, not a treatment for gallstones or a general digestive supplement. Test methods and interpretation matter because inconsistent stimulation can make a normal gallbladder appear abnormal. Administration belongs in a supervised clinical setting.

Sources

1. Calculation of a gallbladder ejection fraction: advantage of continuous sincalide infusion over the three-minute infusion method.
2. Normal values for sincalide cholescintigraphy: comparison of two methods.
3. FDA: KINEVAC approval history (selected product)

Why people are interested. Somapacitan is relevant to people with diagnosed growth-hormone deficiency who need replacement therapy.

What it’s used or studied for. It is a longer-acting growth-hormone medicine. Specific approved growth-related conditions depend on the product label and country.

What studies found. Regulator-reviewed studies found reduced abdominal body fat in deficient adults compared with placebo, and growth in deficient children comparable to daily somatropin. These are replacement-treatment results in diagnosed patients.

Risks and limitations. Headache, swelling, joint pain and high blood sugar are reported effects. It must not be used in certain situations including active tumors or acute serious illness. Benefits in deficiency do not establish anti-aging or athletic enhancement in healthy people.

Sources

1. EMA European public assessment report: Sogroya
2. FDA: SOGROYA approval history
3. DailyMed SOGROYA (SOMAPACITAN-BECO) INJECTION, SOLUTION [NOVO NORDISK]

Why people are interested. Somatropin is relevant when a person has a diagnosed need for growth-hormone replacement or a specifically approved growth disorder.

What it’s used or studied for. It is manufactured human growth hormone, available in different branded products with their own indications. It should not be treated as a single universal wellness product.

What studies found. In one regulator-reviewed comparison, children with growth-hormone deficiency grew similarly with the biosimilar Omnitrope and the reference product Genotropin.

Risks and limitations. Swelling, joint or muscle pain and tingling can occur, particularly in adults. Active tumors and certain acute life-threatening illnesses are important restrictions. Evidence for treating deficiency does not establish longer life, healthy-adult rejuvenation or safe bodybuilding use.

Sources

1. EMA European public assessment report: Omnitrope
2. FDA: OMNITROPE approval history
3. DailyMed NORDITROPIN (SOMATROPIN) INJECTION, SOLUTION [NOVO NORDISK]

Why people are interested. Survodutide attracts interest for improving body weight and blood sugar through two complementary hormone pathways.

What it’s used or studied for. It activates glucagon and GLP-1 receptors. The included phase 2 studies examine adults with obesity and adults with type 2 diabetes.

What studies found. The studies found reductions in body weight, and the diabetes trial also found improved average blood sugar. The degree of weight loss varied with the treatment group.

Risks and limitations. Gastrointestinal adverse events were common in the diabetes trial. Phase 2 improvements do not establish long-term health outcomes or mean that all people will tolerate treatment. Findings from the particular comparison regimens should not be turned into a universal superiority claim.

Sources

1. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
2. Dose-response effects on HbA_1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.

Why people are interested. Interest centers on tissue repair, because TB-500 contains a short sequence related to a natural protein involved in cell movement.

What it’s used or studied for. Here, TB-500 means the acetylated seven-amino-acid fragment, rather than full-length thymosin beta-4. Researchers have examined its chemistry and metabolism in laboratory and animal experiments.

What studies found. The reviewed FDA assessment does not establish that this fragment improves healing in people. Human findings involving the full-length protein cannot simply be transferred to the fragment.

Risks and limitations. Acetylation changes the molecule. Even results with a non-acetylated fragment may differ. The dated HHS conditional compounding policy is separate from FDA approval and proof of clinical benefit.

Sources

1. FDA July 2026 PCAC scientific assessment: TB-500
2. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances
3. HHS notice of availability: FR Doc 2026-22192

Why people are interested. Teduglutide is relevant to people with short bowel syndrome who cannot absorb enough fluid or nutrients after major intestinal loss.

What it’s used or studied for. It mimics GLP-2, a hormone that supports the intestinal lining, with the aim of improving absorption and reducing dependence on intravenous support.

What studies found. A 24-week placebo-controlled study found reductions in the amount of intravenous support needed and in the number of days it was required. Early research also found improved intestinal fluid absorption.

Risks and limitations. Reducing intravenous support is not the same as eliminating it for everyone. These findings concern a serious intestinal-failure condition, and ongoing nutrition management and specialist monitoring remain essential.

Sources

1. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
2. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
3. FDA: GATTEX KIT approval history (selected product)

Why people are interested. Teriparatide is relevant to osteoporosis because it stimulates bone formation, offering a different approach from medicines that mainly slow bone breakdown.

What it’s used or studied for. Approved products are used for particular patients with osteoporosis and increased fracture risk. Teriparatide is a short fragment of parathyroid hormone, rather than the full-length hormone.

What studies found. In a controlled trial in postmenopausal women with osteoporosis, new spine fractures detected on X-rays occurred in 5.0% receiving FORTEO versus 14.3% receiving placebo; both groups also received calcium and vitamin D.

Risks and limitations. The FORTEO label lists nausea and joint pain among common adverse reactions and warns about raised blood calcium and temporary drops in blood pressure on standing. Findings in osteoporosis do not establish general exercise-recovery benefits.

Sources

1. EMA European public assessment report: Forsteo
2. FDA: teriparatide (selected product) approval history
3. DailyMed: Forteo prescribing information

Why people are interested. Terlipressin is relevant when advanced liver disease causes a dangerous decline in kidney function called hepatorenal syndrome.

What it’s used or studied for. In the United States, Terlivaz is approved to improve kidney function in adults with hepatorenal syndrome and rapidly worsening kidney function. It is a hospital treatment, not a general kidney-health supplement.

What studies found. Randomized studies found improved kidney function compared with the control treatments in people with cirrhosis and hepatorenal syndrome.

Risks and limitations. The US prescribing information carries a boxed warning for serious or fatal breathing failure and requires careful oxygen monitoring. Improving kidney function does not by itself establish longer survival, so the benefit must be weighed against substantial risks.

Sources

1. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.
2. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
3. FDA: TERLIVAZ approval history (selected product)
4. FDA approves treatment to improve kidney function in adults with hepatorenal syndrome
5. TERLIVAZ (terlipressin) US prescribing information, updated October 23, 2026

Why people are interested. Tesamorelin interests people with HIV-associated excess deep abdominal fat, a specific pattern that differs from general weight gain.

What it’s used or studied for. It stimulates the body’s growth-hormone release. The included research examines deep abdominal fat and liver fat in people with HIV, plus hormone effects in a small physiology study.

What studies found. A six-month randomized study found less deep abdominal fat and a modest reduction in liver fat compared with placebo.

Risks and limitations. Blood sugar rose early in treatment in that study, although longer-term differences were not significant there. The study was small and did not establish the long-term health consequences of reducing liver fat. These findings do not establish a general anti-aging treatment.

Sources

1. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
2. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.
3. FDA: EGRIFTA approval history (selected product)

Why people are interested. Tesamorelin attracts interest for reducing deep abdominal fat, but the established medical setting is specific.

What it’s used or studied for. In the US, Egrifta is approved for excess abdominal fat in adults with HIV-associated lipodystrophy. The label says it is not indicated for general weight-loss management.

What studies found. A subgroup analysis in people with HIV taking integrase-inhibitor medicines found reductions in deep abdominal and liver fat. It analyzed an existing trial rather than independently confirming the result in a new study.

Risks and limitations. Reduced fat does not establish reduced cardiovascular events. Findings in HIV populations do not establish benefit in healthy adults, and a compounded preparation does not inherit the approved product’s FDA authorization.

Sources

1. FDA: Egrifta approval history
2. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
3. FDA Summary Basis for Regulatory Action: Egrifta (tesamorelin), 10 November 2010
4. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
5. EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]

Why people are interested. Thymosin alpha-1 attracts interest because it influences immune function and has been explored in illnesses involving altered immune responses.

What it’s used or studied for. The included human studies examine severe pancreatitis and a very small group with immune deficiency and depression.

What studies found. A 508-patient pancreatitis trial did not significantly reduce infected pancreatic tissue. A later phase 3 sepsis trial also found no clear mortality benefit: 23.4% died within 28 days with thymosin alpha-1 versus 24.1% with placebo. A five-person uncontrolled mood study remains preliminary.

Risks and limitations. The larger negative trials do not support a broad promise of stronger immunity. The tiny uncontrolled mood findings answer a different question and need larger placebo-controlled confirmation.

Sources

1. Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial.
2. Indications for an antidepressive effect of thymosin alpha-1 in a small open-label proof of concept study in common variable immune deficiency patients with depression.
3. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial

Why people are interested. Thymosin beta-4 is scientifically interesting because it binds actin, a protein that helps cells maintain their shape and move.

What it’s used or studied for. Researchers study its role in cell behavior and tissue repair. The full-length natural peptide is different from the short fragment often called TB-500.

What studies found. The additional sources reviewed establish its sequence and its actin-binding activity. Those biochemical findings do not by themselves demonstrate that administering it improves healing in people.

Risks and limitations. Human trials involving a particular full-length formulation cannot validate every product using a related name. Fragments, preparations and delivery routes may behave differently. Molecular identity is useful context, but it is separate from clinical effectiveness and safety.

Sources

1. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable.
2. UniProtKB P62328: Thymosin beta-4

Why people are interested. Thymulin attracts interest because it links zinc status with aspects of immune-cell function.

What it’s used or studied for. It is a peptide factor associated with the thymus, an organ involved in immune-system development. Its biological activity depends on binding zinc.

What studies found. Small human studies found reduced thymulin activity in mild zinc deficiency, which improved after zinc supplementation. The researchers also observed changes in immune-cell measurements.

Risks and limitations. This does not show that taking thymulin treats an immune disease or slows aging. Correcting zinc deficiency and administering a thymic peptide are different interventions. The small physiology studies do not establish durable health benefits or the safety of thymulin treatment.

Sources

1. Serum thymulin in human zinc deficiency.
2. Contribution of zinc and other metals to the biological activity of the serum thymic factor.

Why people are interested. Tirzepatide can produce substantial weight loss and improve blood sugar in appropriate patients. It acts on two hormone pathways, called GIP and GLP-1, involved in appetite and glucose regulation.

What it’s used or studied for. Zepbound is used with dietary changes and physical activity for long-term weight management in eligible adults. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro has separate diabetes and cardiovascular labeling.

What studies found. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight and a related condition, without diabetes. At 72 weeks, average weight loss across the tirzepatide groups was 15.0% to 20.9%, versus 3.1% with placebo.

Risks and limitations. Nausea, diarrhea and vomiting are common. Serious label warnings include pancreatitis and dehydration-related kidney injury. Zepbound must not be used with a personal or family history of medullary thyroid cancer or MEN 2. It can also affect oral contraceptive effectiveness.

Sources

1. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
2. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
3. FDA: ZEPBOUND approval history (selected product)
4. Zepbound current U.S. prescribing information, revised August 2026
5. Mounjaro current U.S. prescribing information, revised August 2026
6. Tirzepatide Once Weekly for the Treatment of Obesity.

Why people are interested. If you are comparing peptide skincare, tripeptide-10 citrulline is one ingredient name you may encounter. The practical question is whether a particular formulation improves the skin feature you care about.

What it’s used or studied for. It is a defined cosmetic peptide whose identity can be checked against authoritative chemical records. That helps avoid confusing different ingredients with similar names.

What studies found. The sources used for this profile establish identity rather than treatment results in people. They therefore do not answer whether it improves wrinkles, hydration or firmness in a particular skincare product.

Risks and limitations. Identity registration is not a clinical trial, a complete safety assessment or approval as a medicine. Claims about visible benefits need evidence for the actual ingredient, formulation and way it is used.

Sources

1. PubChem compound 90479646: Tripeptide-10 citrulline
2. FDA GSRS substance identity: Tripeptide-10 citrulline

Why people are interested. Triptorelin is considered when reducing hormone signals can help manage certain prostate cancers or stop puberty progressing abnormally early. The intended benefit depends on the patient's diagnosed condition.

What it’s used or studied for. The cited patient guide describes different long-acting injection products for prostate cancer and central precocious puberty, where children begin puberty too soon.

What studies found. Its established treatment role comes from lowering hormones that drive these conditions. The cancer and childhood-puberty uses should not be combined into a general claim that lowering hormones improves health.

Risks and limitations. Hot flushes, changes in sexual function, mood changes and injection reactions can occur. Serious heart or neurological reactions are described, and puberty signs can temporarily worsen when treatment begins.

Sources

1. Triptorelin Injection – MedlinePlus Drug Information
2. FDA: TRELSTAR approval history

Why people are interested. For families affected by Rett syndrome, the interest is in improving symptoms of a serious neurodevelopmental condition and making a difference to daily life, rather than general wellness.

What it’s used or studied for. Trofinetide is the active ingredient in DAYBUE and DAYBUE STIX, U.S.-approved oral products for adults and children age 2 and older with Rett syndrome.

What studies found. Randomized studies reported improvements on some clinician and caregiver assessments compared with placebo. These findings do not mean that every symptom improves or that the disease is cured.

Risks and limitations. Diarrhea, vomiting and weight loss are important drawbacks. The current product label also warns about aspiration and aspiration pneumonia after vomiting.

Sources

1. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome.
2. A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome.
3. Daybue, Daybue Stix current product labeling
4. FDA: DAYBUE approval history (selected product)

Why people are interested. This entry explains the earlier scientific ideas behind a development program. It can help readers understand why related names appear in peptide research without treating them as the same medicine.

What it’s used or studied for. Glycine-proline-glutamate, or GPE, is a naturally derived fragment associated with insulin-like growth factor 1. It is distinct from trofinetide and other modified compounds.

What studies found. The cited studies were in rats, not people. They reported protection of selected nerve-cell measures after experimentally induced injury, which helped motivate further research.

Risks and limitations. These historical experiments do not demonstrate a benefit from taking GPE or predict the results of a different analogue. They are background research, not an additional approved medicine.

Sources

1. N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats.
2. Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic-ischemic injury.

Why people are interested. Vancomycin is an antibiotic, not a recovery or wellness supplement. People may encounter its oral form when certain bacteria cause inflammation of the intestine, sometimes after another antibiotic.

What it’s used or studied for. The cited patient guide describes oral vancomycin for this intestinal infection setting. Oral and intravenous vancomycin have different treatment roles and should not be treated as interchangeable.

What studies found. The established benefit described here is treating susceptible bacteria in the intestine. Oral vancomycin does not kill bacteria elsewhere in the body, and antibiotics do not treat viral colds or flu.

Risks and limitations. Nausea, vomiting and abdominal symptoms can occur, along with potentially serious reactions. Unnecessary antibiotic use also contributes to infections that resist treatment.

Sources

1. Vancomycin: oral medicine information from MedlinePlus
2. FDA: VANCOMYCIN HYDROCHLORIDE approval history

Why people are interested. Vasopressin attracts interest in intensive care because it can tighten blood vessels when septic shock causes dangerously low blood pressure. The important question is whether improving circulation also improves patient outcomes.

What it’s used or studied for. The VANISH trial studied early vasopressin against norepinephrine in 409 adults with septic shock, a life-threatening response to infection with circulatory failure.

What studies found. Vasopressin did not improve the trial's main measure: days alive without kidney failure. The study therefore did not support replacing norepinephrine as initial treatment on the basis of kidney protection.

Risks and limitations. This was an intensive-care comparison, not a wellness study. A negative result for this particular outcome does not mean vasopressin has no medical uses.

Sources

1. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: VANISH
2. FDA: VASOPRESSIN approval history

Why people are interested. Vosoritide is relevant to achondroplasia, a genetic condition affecting bone growth, because it targets a signaling pathway involved in that condition.

What it’s used or studied for. The approved medicine Voxzogo is used in children whose growth plates remain open; the European authorization includes children from four months of age.

What studies found. In a controlled study of children aged five to seventeen, treated children grew about 1.57 centimeters more over a year than those receiving placebo. A separate younger-child study also found improved growth measures.

Risks and limitations. These results do not establish adult height enhancement or general growth promotion. Injection-site reactions, vomiting and reduced blood pressure are recognized side effects. Longer-term functional outcomes are a different question from one-year growth rate.

Sources

1. EMA European public assessment report: Voxzogo
2. FDA: Voxzogo approval history
3. DailyMed VOXZOGO 0.4 MG (VOSORITIDE) KIT VOXZOGO 0.56 MG (VOSORITIDE) KIT VOXZOGO 1.2 MG (VOSORITIDE) KIT [BIOMARIN PHARMACEUTICAL INC.]

Why people are interested. The appeal is pain relief for people with severe, persistent pain when other options have not worked or cannot be tolerated. This is specialist pain care, not a routine wellness peptide.

What it’s used or studied for. PRIALT contains ziconotide and is approved for specified adults who warrant therapy delivered into the fluid around the spinal cord and are intolerant of or refractory to other treatments.

What studies found. A randomized trial found a modest average improvement in pain scores over placebo. Some people had dizziness, confusion, abnormal walking or memory problems.

Risks and limitations. The label carries a boxed warning for severe psychiatric and neurological reactions and excludes patients with a history of psychosis. Delivery requires specialist equipment and supervision.

Sources

1. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
2. PRIALT current product labeling
3. FDA: PRIALT approval history (selected product)

Why people are interested. Zilucoplan is relevant to myasthenia gravis because it blocks part of the immune process that disrupts communication between nerves and muscles.

What it’s used or studied for. The approved medicine Zilbrysq is an additional treatment for adults with generalized myasthenia gravis who have particular acetylcholine-receptor antibodies.

What studies found. In a study of 174 adults, treated patients improved more than placebo on a scale measuring how the disease affects daily activities. That is clinical symptom evidence in a defined autoimmune condition.

Risks and limitations. Blocking this immune pathway increases the risk of meningococcal infection. Vaccination and other safeguards are important parts of the product’s restrictions. These findings do not support using it for ordinary muscle weakness or athletic performance.

Sources

1. EMA European public assessment report: Zilbrysq
2. FDA: Zilbrysq approval history
3. DailyMed ZILBRYSQ (ZILUCOPLAN) INJECTION, SOLUTION [UCB, INC.]